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ABSTRACT 
Minna Piipponen 
Long non-coding RNAs in cutaneous squamous cell carcinoma 
University of Turku, Faculty of Medicine, Dermatology and Venereology, 
Turku Doctoral Programme of Molecular Medicine (TuDMM), Western 
Cancer Centre of the Cancer Center Finland (FICAN West), University of 
Turku and Turku University Hospital, MediCity Research Laboratory, 
University of Turku, Turku, Finland 
Annales Universitatis Turkuensis, Medica-Odontologica, Turku, Finland, 
2019 
 
Long-term exposure to the sun UV-radiation is the leading cause for the 
development of skin cancer. Keratinocyte-derived cutaneous squamous cell 
carcinoma (cSCC) is the most common metastatic skin cancer and its incidence is 
increasing globally. Although the most frequent mutational targets in cSCC 
development have been characterized, a comprehensive understanding of the 
molecular events in cSCC pathogenesis remains incomplete. 
There is an obvious need for clinically useful prognostic biomarkers and 
therapeutic targets for recurrent and metastatic cSCCs. Long non-coding RNAs 
(lncRNAs) are a largely uncharacterized group of regulatory RNAs involved in 
various biological processes and their role in cancer progression is emerging. 
However, their role in cSCC is largely unknown. The main objective of this thesis 
was to investigate lncRNAs in order to identify new biomarkers for progression of 
cSCC and characterize novel therapeutic targets for recurrent and metastatic cSCC. 
In this study two tumorigenic lncRNAs in cSCC were identified, and based on 
their expression and function and with the permission of the HUGO Gene 
Nomenclature Committee they were named PICSAR and PRECSIT. They are 
specifically upregulated in cSCC cells in culture and in vivo and they contribute to 
cSCC progression by distinct mechanisms. PICSAR promotes cSCC cell growth by 
activating ERK1/2 via suppression of DUSP6 expression. Furthermore, PICSAR 
regulates adhesion and migration of cSCC cells by regulating integrin expression. 
PRECSIT expression in cSCC cells was shown to be regulated by the p53 pathway. 
Additionally, PRECSIT was found to regulate invasion of cSCC cells by regulating 
STAT3 signaling and expression of MMP-1, MMP-13, MMP-13, and MMP-10. 
In conclusion, lncRNAs PICSAR and PRECSIT may serve as novel biomarkers 
and putative therapeutic targets in cSCC.   
KEYWORDS: cutaneous squamous cell carcinoma, long non-coding RNA, cancer 
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TIIVISTELMÄ 
Minna Piipponen 
Pitkät ei-koodaavat RNA-molekyylit ihon levyepiteelisyövässä  
Turun yliopisto, Lääketieteellinen tiedekunta, Iho- ja sukupuolitautioppi, 
Turun Molekyylilääketieteen tohtoriohjelma (TuDMM), Läntinen 
Syöpäkeskus (FICAN West), Turun yliopisto ja Turun yliopistollinen 
sairaala, MediCity-tutkimuslaboratorio, Turun yliopisto, Turku, Suomi 
Annales Universitatis Turkuensis, Medica-Odontologica, Turku, Suomi, 
2019 
 
Jatkuva altistuminen auringon UV-säteilylle on suurin syy ihon levyepiteelisyövän 
(cutaneous squamous cell carcinoma, cSCC) kehittymiseen. Se on yleisin 
metastaattinen ihosyöpä maailmanlaajuisesti ja syöpätapausten määrä on kasvussa. 
Useita cSCC:n kehittymiseen liittyviä DNA-mutaatioita on tunnistettu, mutta 
kokonaisvaltainen käsitys syövän kehittymisen aikana tapahtuvista molekulaarisista 
muutoksista on yhä selvittämättä. 
Uusia merkkiaineita tarvitaan, jotta voitaisiin paremmin tunnistaa kehittyykö 
varhaisen vaiheen syöpä aggressiiviseksi metastasoivaksi syöväksi. Pitkät ei-
koodaavat RNA:t (long non-coding RNA, lncRNA) ovat varsin tuntematon ryhmä 
molekyylejä, joiden merkitystä syövässä on tutkittu laajalti, mutta niiden yhteyttä 
cSCC:hen ei juurikaan tunneta. Tämän väitöskirjatyön tavoitteena oli löytää ja 
karakterisoida lncRNA:ita, joita voitaisiin käyttää merkkiaineina nopeasti etenevän 
tai leviävän cSCC:n havaitsemisessa sekä uusien hoitomuotojen kehittämisessä. 
Tässä työssä havaittiin kaksi lncRNA:ta, jotka liittyvät cSCC:n kehittymiseen. 
Tutkimustulosten perusteella sekä ihmisen perimän kansainvälistä kartoitus- ja 
sekvensointihanketta johtavan organisaation nimeämiskomitean luvalla ne 
nimettiin PICSAR:iksi ja PRECSIT:iksi. Niiden ilmentyminen on koholla cSCC:ssä 
ja ne vaikuttavat cSCC:n kehittymiseen eri mekanismeilla. PICSAR edistää syövän 
kasvua aktivoimalla ERK1/2 kinaasia DUSP6:n kautta. Lisäksi se säätelee solujen 
kiinnittymistä ja liikkumista vaikuttamalla integriini-solureseptorien ilmenty-
miseen. PRECSIT:in ilmentymistä säädellään p53-signalointireitin kautta. PRECSIT 
säätelee cSCC-solujen invaasiota STAT3-signalointireitin välityksellä vaikuttamalla 
MMP-1, MMP-3, MMP-10 ja MMP-13 geenien ilmentymiseen.  
PICSAR ja PRECSIT voisivat toimia uusina merkkiaineina syövän diagnos-
tiikassa ja uusien hoitomuotojen kehittämisessä cSCC:lle. 
AVAINSANAT: ihon levyepiteelisyöpä, pitkä ei-koodaava RNA 
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Abbreviations 
AK Actinic keratosis     
BCC Basal cell carcinoma  
circRNA Circular RNA 
cSCC Cutaneous squamous cell carcinoma  
cSCCIS Cutaneous squamous cell carcinoma in situ  
DMBA 9,10-dimethyl-1,2-benzanthracene 
dsRNA Double-stranded RNA 
DUSP Dual-specificity phosphatase 
EGFR Epidermal growth factor receptor 
EMT Epithelial-mesenchymal-transition 
ENCODE Encyclopedia of DNA Elements 
ERK1/2 Extracellular signal-regulated kinase 1/2  
FGFR3 Fibroblast growth factor receptor 3 
FFPE Formalin fixed paraffin embedded  
GAPDH Glyceraldehyde-3-phosphate dehydrogenase  
GENCODE Encyclopædia of genes and gene variants 
gRNA Guide RNA 
HaCaT Non-tumorigenic, spontaneously immortalized human keratinocyte 
cell line 
HE Hematoxylin and eosin 
HGNC The gene nomenclature committee of the human genome 
organization 
HGP The Human Genome Project 
HNSCC Head and neck squamous cell carcinoma 
IHC Immunohistochemistry 
lncRNA Long non-coding RNA 
lincRNA Long intergenic non-coding RNA 
MAPK Mitogen activated protein kinase 
miRNA Micro-RNA 
mRNA Messenger RNA 
MMP Matrix metalloproteinase  
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NAT Natural antisense transcript 
NHEK Normal human epidermal keratinocytes  
ncRNA Non-coding RNA 
NMSC Non-melanoma skin cancer 
ORF Open reading frame 
PICSAR p38 inhibited cutaneous squamous cell carcinoma associated lincRNA 
piRNA Piwi-interacting RNA 
PI3K Phosphoinositide 3-kinase 
PRECSIT p53-regulated carcinoma-associated STAT3 activating long intergenic 
non-protein coding transcript 
pri-miRNA Precursor miRNA 
qRT-PCR Quantitative real-time polymerase chain reaction 
RISC RNA-induced gene silencing complex 
RNA Ribonucleic acid 
RNA-ISH RNA in situ hybridization 
RNA-seq RNA sequencing 
RNA Pol RNA polymerase 
RNP Ribonucleoprotein 
rRNA Ribosomal RNA 
RTK Receptor tyrosine kinase  
SCID Severe combined immunodeficiency  
SK Seborrheic keratosis 
scaRNA Small Cajal-body specific RNA 
siRNA Small interfering RNA  
snRNA Small nuclear RNA 
snoRNA Small nucleolar RNA 
SNP Single-nucleotide polymorphism 
SRP RNA Signal recognition particle RNA 
STAT3 Signal transducer and activator of transcription 3 
TERT Telomerase reverse transcriptase 
TPA Tetradecanoyl-phorbol acetate 
tRNA Transfer RNA 
tsncRNA tRNA-derived small non-coding RNA 
UT-SCC Human cutaneous squamous cell carcinoma cell line  
UV Ultraviolet   
vRNA Vault RNA 
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1 Introduction 
Long-term exposure to solar UV-radiation is the leading cause for the development 
of skin cancer. Keratinocyte-derived cutaneous squamous cell carcinoma (cSCC) is 
the most common metastatic skin cancer and its incidence is increasing globally. 
Primary cSCC arises as a result of malignant transformation of epidermal 
keratinocytes, which primarily occurs due to accumulation of genomic mutations 
after chronic exposure to UV-light. Tumor-suppressor p53 is an important factor in 
protecting the genomic integrity and it is one of the most frequent targets for 
mutational inactivation in keratinocytes. Mutationally inactivated p53 can be 
detected already in actinic keratosis (AK), a potentially malignant skin lesion and the 
first step in cSCC carcinogenesis. However, it is difficult to distinguish which of these 
lesions have the potential to progress to invasive cSCC. Most often primary cSCCs 
can be surgically removed but they harbor a tendency for recurrence and there is a 
poor prognosis for advanced and metastatic cSCCs. 
The mutational background of protein-coding genes in cSCC is generally well 
described, but the role of non-coding RNAs (ncRNA) is largely unknown. In 
addition to the gene regulation by microRNAs (miRNAs) there are several other 
types of functional ncRNAs most likely to be involved in cSCC progression. Long 
non-coding RNAs (lncRNAs) have emerged as important regulatory molecules in 
normal cells, for instance in development and immune response, and there is 
increasing evidence for the role of lncRNAs in human diseases. LncRNAs can 
contribute to the pathogenesis of cancers by mediating the expression of tumor-
promoting or -suppressing genes, and the extracellulary delivered lncRNAs can 
affect gene expression of cells in the surrounding microenvironment.   
The strictly regulated temporal and tissue-specific expression of lncRNAs is a 
major advantage when designing new targeted cancer therapies. In addition, 
differentially expressed lncRNAs can serve as specific prognostic and diagnostic 
molecular markers. Here, the role of lncRNAs in cSCC was studied in culture and in 
vivo. These results provide new evidence for two previously uncharacterized 
lncRNAs, PICSAR and PRECSIT, which are specifically upregulated in cSCC and 
contribute to cSCC progression by distinct functions. 
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2 Review of Literature 
2.1 Cutaneous squamous cell carcinoma 
2.1.1 Overview 
Cancer arises from genetic alterations in the genome allowing transformation of 
normal human cells into malignant (reviewed in Hanahan & Weinberg, 2000). It is 
well known that a long-term sun ultraviolet (UV) exposure predisposes to 
accumulation of epidermal DNA-damage and eventually to development of skin 
cancer (reviewed in Narayanan et al, 2010; Matsumura & Ananthaswamy, 2004). 
Nevertheless, skin cancers are the most common cancer types globally with 
increasing incidence, especially among Caucasian population (Lomas et al, 2012; 
reviewed in Leiter et al, 2014). 
Cutaneous squamous cell carcinoma (cSCC) is a non-melanoma skin cancer 
(NMSC) and the second most common malignancy after basal cell carcinoma (BCC) 
(Lomas et al, 2012). It is one of the most common cancers globally with a varying 
annual incidence rate between 13 and 77 cases per 100 000 persons in Europe 
(Callens et al, 2016; Rubió-Casadevall et al, 2016; Eisemann et al, 2014; Korhonen et 
al, 2019; Venables et al, 2019) and  up to 270 cases per 100 000 persons in Australia 
(Pandeya et al, 2017; Keim et al, 2015). Collectively, the incidence of cSCC is 
continuously increasing worldwide (Rogers et al, 2015; Robsahm et al, 2015; 
Umezono et al, 2019; Birch-Johansen et al, 2010; Lomas et al, 2012). To distinguish 
cSCCs and BCCs from other less common NMSCs they are often referred to as 
“keratinocyte carcinomas” as they both originate from keratinocytes (reviewed in 
Nehal & Bichakjian, 2018). However, they are two distinct types of skin cancers and 
a careful diagnosis is required to distinguish the low and high risk tumors and to 
choose the right clinical management (reviewed in Nehal & Bichakjian, 2018). To 
emphasize their different pathologies, cSCCs have a risk to metastasize and there is 
a poor prognosis for metastatic and recurrent cSCCs whereas BCCs rarely 
metastasize (reviewed in Verkouteren et al, 2017; Burton et al, 2016). Even though 
the mortality rate of cSCC is relatively low, approximately 3 % (Schmults et al, 2013; 
Czarnecki, 2017; Robsahm et al, 2015), the overall high incidence of cSCC and other 
Review of Literature 
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NMSCs poses not only a financial burden to the health care but it has a major impact 
on the patients’ quality of life (reviewed in Gaulin et al, 2015). 
2.1.2 The pathogenesis of cSCC 
The major risk factor for cSCC is the cumulative exposure to sun UV-light (reviewed 
in Green & Olsen, 2017). Additionally, indoor tanning is associated with increased 
risk for cSCC, especially at young age (Wehner et al, 2012). Other risk factors include 
immunosuppression, chronic non-healing wounds, tobacco smoking, human 
papillomavirus infection and certain chemical exposures such as pesticides 
(reviewed in Green & Olsen, 2017). There are also rare hereditary disorders, such as 
xeroderma pigmentosum and epidermolysis bullosa, which are associated with a risk 
for cSCC development due to mutations in key signaling factors or genes essential 
for functional epidermal structure (reviewed in Green & Olsen, 2017). 
The development of cSCC is a multistep process that involves accumulation of 
several molecular and cellular changes before resulting in a visible skin cancer 
(reviewed in Seebode et al, 2016). Actinic keratoses (AKs) indicate an early sign of 
cSCC development. They are epidermal keratinocytic dysplasia, usually seen as 
thickened or scarly skin patches resulting from chronic sun exposure (reviewed in 
Cockerell, 2000). A more progressed form of skin carcinogenesis is carcinoma in situ 
where atypical keratinocytes extend throughout the whole epidermis (reviewed in 
Cockerell, 2000). If these lesions are not treated they have a risk to progress into 
invasive cSCC (Schmults et al, 2013; reviewed in Ratushny et al, 2012). 
2.1.2.1 Harmful effects of the sun exposure 
The solar UV-radiation is divided into three subgroups based on their wave lengths; 
UVA (320-400 nm), UVB (290-320 nm) and UVC (100-280 nm), of which UVA is 
the predominant form that reaches the earth, and it penetrates to the dermal layer of 
skin (Figure 1) (reviewed in Matsumura & Ananthaswamy, 2004). UVA is less 
carcinogenic than UVB and UVC as it is weakly absorbed by DNA, but it induces 
indirect DNA-damage by oxidative stress and promotes skin aging and wrinkling 
(reviewed in Yaar & Gilchrest, 2007). UVC is strongly mutagenic having the highest 
energy but it does not penetrate the ozone layer, thus the harmful biological effects 
of the UV-radiation are mainly caused by the UVA and UVB (reviewed in 
Matsumura & Ananthaswamy, 2004; Valejo Coelho et al, 2016). UVB, even though 
constituting a minor part of the ambient UV-radiation, is absorbed in the skin 
epidermis (Figure 1) and it is responsible in inducing DNA-damage, oxidative stress 
and immunosuppression (reviewed in Matsumura & Ananthaswamy, 2004; Valejo 
Coelho et al, 2016). In contrast to UVA, UVB is directly absorbed by DNA and it 
Minna Piipponen 
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interferes nucleotide base pairing. This results in formation of DNA photoproducts, 
such as cyclobutane dimers between thymine (T) or cytosine (C) residues, or 
pyrimidine-pyrimidone (6–4) photoproducts (reviewed in Pfeifer et al, 2005). These 
lesions can lead to DNA-mutations, also known as “UV-signature mutations” 
characteristic of C→T transitions and CC→TT mutations, if the DNA repair system 
fails to correct them (Brash, 2015; reviewed in Matsumura & Ananthaswamy, 2004). 
This is why the UVB exposure is particularly efficient in promoting skin 
carcinogenesis. In addition to UV-radiation, a considerable part of the energy that is 
emitted by the sun is infrared (IR) radiation (760 nm – 1 mm) (Figure 1). It is capable 
of penetrating to the epidermis, dermis and subcutaneous tissue (reviewed in 
Krutmann et al, 2012). Primarily, it causes a temperature increase in the skin. 
However, there is increasing evidence that a long-term IR exposure contributes to 
premature skin aging in addition to UVA (reviewed in Krutmann et al, 2012). 
 
Figure 1. A schematic view of the skin structure and implications of acute and chronic 
ultraviolet radiation. Adapted from Matsumura & Ananthaswamy, 2004. 
Review of Literature 
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2.1.2.2 Molecular changes in cSCC pathogenesis 
cSCC is a cancer with a very high mutational burden. Prevalent C→T transitions have 
been detected in cSCC tumors, which presents a typical mutational signature caused 
by UVB-irradiation (Pickering et al, 2014; Inman et al, 2018; South et al, 2014; Cho 
et al, 2018; Li et al, 2015; Mueller et al, 2019). An average mutational frequency of 
more than 50 mutations per mega base pair of DNA is higher than in any other 
common tumor types, for instance melanoma, lung or colorectal cancer (Pickering 
et al, 2014; South et al, 2014). In a genomic point of view cSCC is a very complex 
disease with a high level of heterogeneity (Inman et al, 2018; South et al, 2014; Li et 
al, 2015), which makes it a challenging target for cancer therapy. 
2.1.2.2.1 Inactivated tumor suppressor genes in cSCC 
The consequences of acute UVR (Figure 1) include tan or sunburn, immune 
suppression and DNA-damage (reviewed in Matsumura & Ananthaswamy, 2004). 
DNA-damage leads to the activation of the p53 protein which is one of the most 
central factors in maintaining genomic stability and controlling cellular responses, 
such as cell proliferation and apoptosis (reviewed in Levine, 1997). Unfortunately, 
p53 is a common target for genetic alterations in many cancers, especially in UV-
induced skin cancers and cSCC (Pickering et al, 2014; Inman et al, 2018; South et al, 
2014; Cho et al, 2018; Li et al, 2015). This is the case particularly with metastatic 
cSCCs with nearly 95 % of samples detected with genetic alterations in the TP53 gene 
(Pickering et al, 2014; Li et al, 2015) in comparison to primary cSCCs with a 
mutational frequency closer to 50-60 % (South et al, 2014; Yilmaz et al, 2017). 
Moreover, p53 mutations are frequently found already in actinic keratosis (Campbell 
et al, 1993; Ziegler et al, 1994; Taguchi et al, 1994), highlighting the carcinogenic role 
of chronic UVR (Figure 1) in cancer initiation. Loss of p53 function allows cells to 
bypass apoptosis resulting in clonal expansion of the mutated cells which further 
increases the mutation frequency (reviewed in Benjamin & Ananthaswamy, 2007; 
Brash, 2006). Overall, cSCC harbors a very high mutation rate compared to other 
common cancers, such as breast cancer or melanoma (Pickering et al, 2014; South et 
al, 2014; Li et al, 2015; Inman et al, 2018). In vivo studies have shown that p53 
mutations arise very early on in mouse skin after UVB exposure and the growth of 
the p53-mutant keratinocytes is driven by UVB (Zhang et al, 2001; Melnikova et al, 
2005; Kramata et al, 2005). Consistent with this, p53 mutations are also present in 
sun-exposed normal human skin among many other cancer driver genes 
(Martincorena et al, 2015). 
In addition to p53, p16(INK4a) and p14(ARF) are important cell cycle 
regulators and commonly non-functional in cSCC due to inactivating mutations in 
the CDKN2A gene encoding these proteins (Brown et al, 2004; Pickering et al, 2014; 
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South et al, 2014; Li et al, 2015; Al-Rohil et al, 2016; Inman et al, 2018; Cho et al 
2018). CDKN2A mutations are found also in actinic keratosis, although less 
frequently than in cSCC (Mortier et al, 2002; Kanellou et al, 2008). Interestingly, 
CDKN2A is not mutated in the sun-exposed normal skin (Martincorena et al, 2015), 
indicating that CDKN2A inactivation occurs at a later stage in the progression from 
actinic keratosis to cSCC. Other less common mutational targets in cSCC include 
CCDN1 and MYC genes, also responsible in cell cycle regulation (Li et al, 2015; Al-
Rohil et al, 2016; Toll et al, 2009), however they may play a more specific role in the 
progression of oral SCCs (Martín-Ezquerra et al, 2010; Akervall et al, 2003). The 
inactivation of cell cycle regulators, such as p53 and p16(INK4a), gives cells a growth 
advantage and it predisposes them to genomic instability, however many other 
mutations are needed to contribute tumorigenesis (Figure 2) (reviewed in Dotto & 
Rustgi, 2016). When mutated, these target genes further promote uncontrolled cell 
growth and they may have a preferential role in cSCC progression by interfering cell 
differentiation.  
 
Figure 2. Early genetic alterations and signaling pathways involved in cSCC progression. 
Activating (*) and inactivating (**) mutations are indicated with one or two asterisks and the 
consequent activation or inactivation with a red and blue colors, respectively. 
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Notch signaling is an evolutionary conserved pathway with a key role in regulating 
cellular development and it plays a pivotal role in controlling normal skin 
homeostasis and function (reviewed in Nowell & Radtke, 2013). Notch1 promotes 
keratinocyte differentiation and it is involved in maintaining the functional skin 
barrier (reviewed in Lefort & Dotto, 2004). Emphasizing its important regulatory 
role in the skin, loss of Notch1 results in skin tumorigenesis. (Figure 2) (reviewed in 
Nowell & Radtke, 2013). Notch1 has been shown to mediate tumor suppression by 
reducing p63 expression, leading to inhibition of cell growth and induced 
differentiation (Nguyen et al, 2006). It can also function via p53 to suppress 
ROCK1/2 and MRCKα kinases or induce tumor suppressor protein p21 expression 
leading to cell growth inhibition (Lefort et al, 2007; Rangarajan et al, 2001). 
Additionally, Notch1 can regulate cSCC tumorigenesis by modulating inflammatory 
response and tumor microenvironment (Demehri et al, 2008 and 2009; Di Piazza et 
al, 2012). NOTCH1 and NOTCH2 are frequently mutated in cSCC, resulting in 
truncated Notch receptors and abrogated signaling (Wang et al, 2011; Pickering et 
al, 2014; South et al, 2014; Li et al, 2015; Al- Rohil et al, 2016; Inman et al, 2018; Cho 
et al, 2018). NOTCH1 mutations occur early in cSCC progression, which is proposed 
to be a downstream consequence of mutated p53 as NOTCH1 is a direct 
transcriptional target for p53 in keratinocytes (South et al, 2014; Lefort et al, 2007). 
In addition, NOTCH1 mutations are considerably common in sun-exposed normal 
skin, supporting the tumorigenic role for p53 and Notch mutations in early skin 
carcinogenesis (Martincorena et al, 2015; South et al, 2014). 
2.1.2.2.2 Mutationally activated oncogenes in cSCC 
HRas is a well-studied member of the Ras GTPase subfamily responsible in 
controlling a wide range of cellular pathways, such as the mitogen-activated protein 
kinase (MAPK) signaling, and it acts as a proto-oncogene in many different cancers 
(reviewed in Pylayeva-Gupta, 2011). Activating mutations in the HRAS gene are 
frequently found in cSCC, in addition to less common NRAS and KRAS mutations 
(Pickering et al, 2014; South et al, 2014; Bamford et al, 2004; Li et al, 2015; Al-Rohil 
et al, 2016; Inman et al, 2018; Cho et al, 2018). The proportion of HRAS mutations is 
particularly high in cSCCs treated with BRAF-inhibitor vemurafenib, which is a 
commonly used treatment for melanoma (Su et al, 2012; Oberholzer et al, 2012; 
South et al, 2014). The adverse effect of the drug is caused by a paradoxical MAPK 
activation and accelerated growth of HRAS mutated lesions (Su et al, 2012; reviewed 
in Wu et al, 2017). Interestingly, the BRAF-inhibitor induced cSCCs with mutated 
HRAS harbor higher number of NOTCH1 mutations when compared to sporadic 
cSCCs, implicating Notch1 as an important factor in HRas driven skin 
carcinogenesis (Figure 2) (South et al, 2014). The loss of Notch1 signaling alone is 
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not sufficient for tumor formation in mice (Lefort et al, 2007). However, when 
combined with oncogenic Hras expression there is aggressive tumor formation 
whereas oncogenic Hras expression alone results in only small nodules or no tumors 
at all (Lefort et al, 2007). 
The most commonly used mouse model for cSCC is generated by topically 
applying a highly carcinogenic agent 9,10-dimethyl-1,2-benzanthracene (DMBA) to 
mouse skin (Abel et al, 2009). During the first stage of skin carcinogenesis DMBA 
causes genetic alterations of which the Hras gene is the primary target (Abel et al, 
2009; Nassar et al, 2015). Second, a treatment with a tumorigenic agent, such as 
tetradecanoyl-phorbol acetate (TPA) enables the clonal expansion of the cell 
population carrying Hras mutation, resulting in sustained epidermal hyperplasia and 
skin tumors (Abel et al, 2009). Overall, the histology and the genomic background 
of the mouse DMBA/TPA-induced cSCCs are very similar to human cSCCs (Nassar 
et al, 2015). Sustained activation of Hras results in a marked induction of epidermal 
growth factor receptor (EGFR) and its ligands in cSCC mouse model (Casanova et 
al, 2002; Dlugosz et al, 1995). EGFR is also a target for mutational activation in 
human cSCC (Li et al, 2015; Al-Rohil et al, 2016). EGFR plays an important role in 
normal epidermal homeostasis, but sustained EGFR activity can further induce Ras 
signaling and uncontrolled cell growth and survival via MAPK and phosphoinositide 
3-kinase (PI3K) signaling downstream of Ras (Figure 2) (reviewed in Doma et al, 
2013).  
Another important signaling factor downstream of EGFR is the signal transducer 
and activator of transcription 3 (STAT3). STAT3 plays an important role in normal 
epithelia in skin wound healing promoting keratinocyte migration (Sano et al, 1999) 
but aberrant STAT3 activity contributes to skin carcinogenesis (Chan et al, 2008; 
Kataoka et al, 2008; reviewed in Macias et al, 2013; Sano et al, 2008). STAT3 
activation is also strongly associated with inflammation and development of 
psoriasis (reviewed in Calautti et al, 2018). Activating mutations in the STAT3 gene 
are not found in cSCC but its tumorigenic function is strongly dependent on 
activated growth factor signaling, for example via EGFR (reviewed in Macias et al, 
2013; Sano et al, 2008). EGFR-mediated STAT3 activation promotes tumorigenesis 
in DMBA/TPA-induced mouse cSCCs (Chan et al, 2004). Expression of 
constitutively active Stat3 in mouse skin drives rapid cSCC progression and these 
tumors are highly vascularized and poorly differentiated (Chan et al, 2008). By 
contrast, Stat3-deficiency drives keratinocytes to apoptosis after DMBA-treatment 
and tumor formation is completely prevented in Stat3-deficient mice after 
DMBA/TPA-treatment (Chan et al, 2004). Stat3 is rapidly deactivated and 
downregulated in keratinocytes upon UVB exposure, however repeated UVB 
exposure results in constitutively active Stat3 in mouse cSCCs (Sano et al, 2005). In 
consistent with this, expression of constitutively active Stat3 in mouse epidermis 
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results in epidermal hyperproliferation after UVB exposure, whereas keratinocytes 
of Stat3 deficient mice are highly sensitive to apoptosis after UVB exposure (Kim et 
al, 2009). The levels of Stat3 target genes, such as cell cycle regulator cyclin D1 and 
anti-apoptotic Bcl-xL correlate with Stat3 expression in both mouse models, 
indicating Stat3 as an important regulator in UVB-induced skin carcinogenesis (Kim 
et al, 2009). 
Receptor tyrosine kinases (RTKs) are cell surface receptors important in a wide 
range of cellular processes, and RTK gene amplifications and activating mutations 
are commonly found in cancer (reviewed in Schlessinger, 2000). The majority of 
activating mutations in cSCC are associated with Ras, RTK and PI3K pathway genes 
(Li et al, 2015). Most frequently mutated or amplified RTK genes in cSCC include 
EGFR, FGFR3, KIT and ERBB4 (Li et al, 2015; Al-Rohil et al, 2016). ERBB4 and 
FGFR3 belong to the same RTK family with EGFR. The role of ERBB4 mutations in 
non-melanoma skin cancer is not well known but they have been implicated in 
cutaneous melanoma (Lau et al, 2014; Manca et al, 2013). Nevertheless, it remains 
controversial whether they act as driver or passenger mutations in melanoma. 
Activating FGFR3 mutations are common in seborrheic keratoses (SK), which are 
benign epidermal hyperplastic papillomas, but the mutationally activated FGFR3 is 
not sufficient for the development of cSCC, in accordance with a low rate of FGFR3 
mutations in cSCC (Hafner et al, 2010; Duperret et al, 2014). 
Overall, skin carcinogenesis is a complex process involving several genetic 
alterations before cells acquire an invasive phenotype. Based on several genomic 
analyses of cSCC tumors and cell lines the most profound mutations in driving cSCC 
tumorigenesis are characterized, such as p53, HRas and Notch1 (Figure 2). In 
addition to these other mutated oncogenes have been identified in cSCC, such as 
PIK3CA, MTOR and KIT, and mutated tumor suppressors genes FAT1 and KMT2C 
(Li et al, 2015; Pickering et al, 2014; Al-Rohil et al, 2016; Inman et al, 2018). The 
question remains, what is the order and combination of these alterations in cancer 
initiation and progression, as some of them are found already in normal sun-exposed 
skin without any sign of malignancy. It seems that the number of driver mutations 
per cell is a major contributor to cancer progression, as these cells are clonally 
expanding and increasing the genomic instability and mutational burden 
(Martincorena et al, 2015). 
2.1.2.2.3 Epigenetic changes in cSCC 
Genomic DNA-alterations are not solely driving carcinogenesis but epigenetic 
deregulation is a well-recognized phenomenon in cancer, allowing cells to activate 
or repress gene transcription by chromatin modifications (reviewed in Dawson, 
2017). Many cancer types exhibit hypermethylation of gene promoters, which leads 
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to transcriptional gene repression (reviewed in Clark & Melki, 2002). In cSCC certain 
tumor-suppressors, such as p16(INK4a), p14(ARF), the inflammasome adaptor ASC 
and E-cadherin have been detected with hypermethylated gene promoter and gene 
inactivation (Brown et al, 2004; Murao et al, 2006; Meier et al, 2016; Chiles et al, 
2003). Chronic UVA-irradiation has been also shown to induce hypermethylation of 
the P16(INK4a) gene promoter in HaCaT keratinocytes (Chen et al, 2012). In 
accordance, UVB- and DMBA/TPA-induced mouse skin tumors exhibit differential 
epigenetic regulation and some of these changes reflect the aberrant DNA-
methylation of human cSCCs (Yang et al, 2014, 2019; Fraga et al, 2004). When cSCC 
and AK methylation profiles have been examined it is interesting that they show a 
similar, aberrant methylation pattern with cancer-specific features when compared 
to healthy epidermis (Rodríguez-Paredes et al, 2018), indicating UV-induced 
epigenetic deregulation during skin carcinogenesis. In addition, two distinct keratin 
methylation profiles could be detected in AK and cSCC lesions, suggesting two 
subclasses of AK and cSCC originating from different keratinocyte differentiation 
stages (Rodríguez-Paredes et al, 2018).  
In contrast to hypermethylation a global decrease in DNA-methylation, or 
hypomethylation, has been also observed in cancer (reviewed in Ehrlich, 2009). In 
accordance, hypomethylation is associated with aging and sun exposure of the 
epidermis (Vandiver et al, 2015). Moreover, the same hypomethylated areas in the 
non-malignant sun-exposed lesions were shown to be hypomethylated in cSCCs 
(Vandiver et al, 2015), highlighting the carcinogenic effect of UV-irradiation in skin 
carcinogenesis.  
2.1.2.2.4 Telomerase activity in cSCC 
As described in the previous examples, the high burden of UV-induced mutations in 
cSCCs and sun-exposed skin contribute to deregulation of many important signaling 
proteins, eventually resulting in skin cancer (Figure 2). It is important to note that 
mutations in the gene regulatory areas, such as gene promoters and enhancers can also 
have adverse consequences regarding tumorigenesis. Recently, activating mutations in 
the TERT gene promoter have been reported in several cancer types and they seem to 
be particularly prevalent in cutaneous melanoma, BCC and cSCC (Pópulo et al, 2014; 
Griewank et al, 2013; Scott et al, 2014). These mutations lead to induced expression of 
the gene encoding telomerase reverse transcriptase, a catalytically active subunit of 
telomerase (Sauerwald et al, 2013). Telomerase has a key role in the normal 
physiological state in protecting the telomeric DNA in the chromosome ends and in 
preventing the replicative senescence of proliferating cells. However, reactivation of 
telomerase activity allows telomere elongation and unlimited cell replication, one of 
the hallmarks of cancer (reviewed in Hanahan & Weinberg, 2000).  
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Paradoxically, progressive telomerase shortening due to impaired telomerase 
activity can lead to chromosome instability as the unprotected telomere ends can form 
chromosome fusions (reviewed in Hanahan & Weinberg, 2000). This would normally 
lead to cell cycle arrest, however if the cell escapes the cellular checkpoint because of a 
defective p53 the genomic instability is passed to the next progeny (reviewed in Artandi 
& DePinho, 2010). This may be an important driver of epithelial carcinogenesis, as p53 
is one of the first targets of mutational inactivation in skin cancer. Indeed, two distinct 
telomere phenotypes are characterized in cSCCs; short/intermediate telomeres with a 
conserved size in all tumor areas and intermediate/long telomeres with increased 
variation in size within different tumor areas (Leufke et al, 2014). Similar subgroups are 
present in immunosuppression induced cSCCs, suggesting two different mechanisms 
for cancer initiation (Leufke et al, 2014). Interestingly, the short/intermediate telomeres 
correlate with low p53 expression, vice versa high p53 expression is more often detected 
in the cSCCs with intermediate/long telomeres. Additionally, the number of aberrant 
cells and telomeric aggregates, a sign of telomeric fusions, is increased with tumor 
progression from actinic keratosis to cSCC (Leufke et al, 2014). In another study 
telomere length was shown to be shorter in cSCC compared to actinic keratosis and 
carcinoma in situ, indicating a correlation in telomere shortening and cSCC 
progression (Yamada-Hishida et al, 2018). 
2.1.2.2.5 Molecular changes driving cSCC invasion  
In order for epithelial cells to gain a motile phenotype they must undergo a process 
called epithelial-mesenchymal-transition (EMT), a common strategy for cancer cells 
to become invasive (reviewed in Skrypek et al, 2017). A subpopulation of migratory 
cancer cells that have undergone EMT can be found in patient derived cSCC cell lines 
and the proportion of these cells correlate with tumor progression (Biddle et al, 
2011). Additionally, based on in vivo studies the cancer cell of origin affects the 
ability of the tumor cells to undergo EMT. The cSCC tumors originating from mouse 
hair follicles are more prone to EMT and metastasis when compared to tumors 
originating from the interfollicular epidermis (Latil et al, 2017). Invasive human 
cSCC tumors often exhibit low expression of cell-cell adhesion markers, such as E-
cadherin, and induced expression of vimentin and podoplanin as a sign of EMT 
(Barrette et al, 2014; Toll et al, 2013; Hesse et al, 2016). 
When comparing actinic keratosis or carcinoma in situ with invasive cSCCs, it is 
evident that expression of matrix metalloproteinases (MMPs) is one key step in order 
cells to become invasive (Inman et al, 2018; Ra et al, 2011; Lambert et al, 2014; Mitsui 
et al, 2014; García-Díez et al, 2019; reviewed in Nissinen & Kähäri, 2014). 
Reorganization of the extracellular matrix is needed so that the cells are able to 
invade to the surrounding tissue. Together with MMP activation loss of basement 
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membrane collagen is associated with cSCC progression (reviewed in Kerkelä & 
Saarialho-Kere, 2003). The tumor microenvironment plays an important role in 
cSCC progression and MMPs are capable of regulating activity of several 
chemokines, cytokines and growth factors to promote inflammation and cancer 
progression (reviewed in Nissinen & Kähäri, 2014). On the other hand, 
immunosuppression is a major risk factor for cSCC development and MMPs can 
regulate inflammation in a way that it helps the cancer cells escape the immune 
surveillance (reviewed in Nissinen & Kähäri, 2014).  
2.1.3 The diagnosis, treatment and prognosis of cSCC 
In addition to a clinical examination a skin biopsy is required for cSCC diagnosis. 
Based on several parameters, such as the tumor size, location and histologic subtype 
tumors can be classified into cSCCs with high or low metastatic potential (reviewed 
in Nehal & Bichakjian, 2018; Kallini et al, 2015; Burton et al, 2016). For example, 
poorly differentiated cSCCs with perineural invasion and more than 2 mm thickness 
possess a high risk for metastasis (reviewed in Kallini et al, 2015; Burton et al, 2016). 
In general, patients with a primary, low-risk cSCC that can be surgically removed have 
a good prognosis. However, patients with distant metastases are associated with poor 
outcome and high mortality (reviewed in Burton et al, 2016). Special attention should 
be given to immunosuppressed patients in order to prevent cSCC development 
(reviewed in Burton et al, 2016). Radiation and chemotherapy can be used for 
advanced and recurrent high-risk tumors that cannot be completely removed 
surgically, especially for tumors located in the facial area (reviewed in Kallini et al, 
2015; Que et al, 2018). Other targeted therapies, such as EGFR and mTOR inhibitors 
may be beneficial in cSCC treatment, however there is always a risk for cancer cells 
acquiring drug resistance (reviewed in Harwood et al, 2016). Recently, PD-1 targeting 
immunotherapy has been shown to be a promising treatment for patients with 
metastatic or locally advanced cSCCs (Migden et al, 2018). 
There is an urgent need for clinically useful prognostic biomarkers for predicting 
the risk of recurrence and metastatic potential of cSCC from early stage. Several 
promising cSCC biomarkers have been discovered, such as certain matrix 
metalloproteinases (reviewed in Kerkelä & Saarialho-Kere, 2003), cell surface 
tyrosine kinase receptor EphB2 (Farshchian et al, 2015), inflammation related 
SerpinA1 (Farshchian et al, 2011), AIM2 (Farshchian et al, 2017a) and several 
complement system proteins (Riihilä et al, 2014; 2015; 2017). Additionally, ATF3 
transcription factor (Dziunycz et al, 2014), the IKK kinase complex (Toll et al, 2015), 
epigenetic regulators p300, PCAF and EZH2 (Bosic et al, 2016; Hernández-Ruiz et 
al, 2018), and certain miRNAs (reviewed in Yu & Li, 2016) could serve as molecular 
biomarkers and important therapeutic targets for cSCC.  
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2.2 Non-coding RNAs 
2.2.1 The short history of non-coding RNAs 
DNA-transcription is a process where genetic information from genomic DNA is 
transcribed to RNA. This is carried out mainly by RNA polymerase II (RNA Pol II) 
that enzymatically converts DNA to messenger RNAs (mRNAs), which are then 
translated into proteins (reviewed in Hurwitz, 2005). Not all DNA is encoded into 
proteins, but a significant part is transcribed into so called non-coding RNAs 
(ncRNAs) (reviewed in Djebali et al, 2012; Jacquier, 2009). The transfer RNA (tRNA) 
and ribosomal RNA (rRNA) were discovered in the 1950s providing the first 
evidence of the functional importance of ncRNAs (Hoagland et al, 1958; Palade, 
1955). Later on in the 1980s the first RNA enzymes, “ribozymes”, were discovered 
(reviewed in Reymond et al, 2009). RNA polymerase I (RNA Pol I) is mainly 
responsible for rRNA synthesis and RNA polymerase III (RNA Pol III) for the 
synthesis of tRNA and 5S rRNA component of the ribosome, which are all necessary 
for protein translation (Roeder & Rutter 1969). Therefore, there would not be any 
protein without RNA. In addition to them, many other RNAs are involved in the 
complex regulation of protein synthesis, including small nuclear RNAs (snRNAs) 
(Reddy & Busch, 1983) and telomerase RNA (reviewed in Wang & Feigon, 2017).  
With the help of an international consortium and an enormous amount of time 
and money invested in the Human Genome Project (HGP) in the 1990s, followed by 
new projects such as the 1000 Genomes Project (1KGP), the Encyclopedia of DNA 
Elements project (ENCODE) and the Encyclopædia of genes and gene variants 
project (GENCODE), we have broadened our knowledge of the human genomic 
landscape (Harrow et al, 2012; reviewed in Moraes & Góes, 2016). Based on the 
current statistics from the GENCODE project the number of genes in the human 
genome is around 60 000 of which protein coding genes make up almost one third, 
19 881 genes (GENCODE version 21). This is quite close to what some of the 
scientists estimated in the early 2000 before completing the HGP despite the most 
extreme guesses (Pennisi, 2000). What was not known at the time that the amount 
of non-protein coding genes would be almost twice as much as protein coding genes 
(ENCODE Project Consortium, 2012). However, the exact number of protein and 
non-protein coding transcripts is difficult to determine because of complex 
expression patterns and variability between tissue types and individuals, and 
regulation of transcription (reviewed in Pertea, 2012). The current GENCODE 
estimation for the total number of gene transcripts is nearly 200 000 (GENCODE 
version 21), but as well as the total number of genes, this is dependent of many factors 
and will most likely change over time. 
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2.2.2 Biogenesis and classification of ncRNAs 
The biogenesis and molecular functions of ncRNAs differ greatly from each other. 
They are roughly classified into infrastructural and regulatory ncRNAs (reviewed in 
Mattick & Makunin, 2006) (Figure 3). The infrastructural ncRNAs are so-called 
housekeeping genes with well-defined cellular functions. They are RNAs mainly 
involved in protein synthesis including tRNAs, rRNA, telomerase RNA, small 
nucleolar RNAs (snoRNAs) with small Cajal-body specific RNAs (scaRNAs) and 
small nuclear RNAs (snRNAs) or commonly referred to as spliceosomal uRNAs. In 
addition, signal recognition particle RNAs (SRP RNAs) and vault RNAs (vRNAs or 
vtRNAs) are also considered as infrastructural ncRNAs (reviewed in Mattick & 
Makunin, 2006). The human SRP RNA, also known as 7SL RNA, is the RNA-
component of the signal recognition particle ribonucleoprotein complex and it has 
an important role in signal peptide binding during protein translocation to the cell 
membrane (Walter & Blobel, 1982). It has a similar role also in archaea, bacteria and 
plants (reviewed in Rosenblad et al, 2009). Likewise, the vRNAs are evolutionary 
conserved and bound to proteins, forming large ribonucleoprotein particles in cells 
(Kedersha & Rome, 1986) however their exact cellular function still remains unclear. 
They have been suggested to have a role in intracellular trafficking (reviewed in van 
Zon et al, 2003) and more recently in immune response (Li et al, 2015), drug 
resistance (Gopinath et al, 2010; Persson et al, 2009) and apoptosis (Amort et al, 
2015). Similar to vRNAs some infrastructural RNAs have additional functional roles 
beside protein synthesis (reviewed in Hu et al, 2012). For instance, tRNA-derived 
small non-coding RNAs (tsncRNAs) are newly defined small functional ncRNAs 
generated from tRNAs by specific endonuclease cleavage and their dysregulation has 
been detected in cancer and other human diseases (reviewed in Zhu et al, 2018). 
Regulatory ncRNAs function mostly by base-pairing with DNA or RNA 
(reviewed in Quinn & Chang, 2016; Guil & Esteller, 2015), or by interacting directly 
with proteins (reviewed in Hogg & Collins, 2008). There is also cross-talk between 
different ncRNAs (reviewed in Yamamura et al, 2018). Conventionally they are 
classified into small or long non-coding RNAs (lncRNAs) based on their length 
(Figure 3). LncRNAs are considered as ncRNAs larger than 200 nucleotides in size, 
and everything smaller than that are termed small or short ncRNAs (Kapranov et al, 
2007). Some pseudogenes can be also transcribed into lncRNAs (reviewed in 
Grandér & Johnsson, 2016). This kind of division, however, is not absolute as for 
instance some lncRNAs are less than 200 nucleotides in size. Also, some lncRNAs 
can function both as regulatory lncRNAs and they can be processed to yield small 
ncRNAs (reviewed in Ma et al, 2013). There is also some overlapping between these 
subgroups as some ncRNAs may have functional duality, such as snRNAs and 
snoRNAs which have additional functional roles aside their well-known role as 
infrastuctural RNAs (Li et al, 2012; Chen & Heard, 2013; reviewed in Dupuis-
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Sandoval et al, 2015). In Figure 3 they are included in both groups, as infrastructural 
and small regulatory ncRNAs.  
 
Figure 3. Classification of ncRNAs based on their structure and function. 
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2.2.3 MicroRNAs and other small ncRNAs  
Small ncRNAs are typically divided into three subgroups based on their structure 
and function, including microRNAs (miRNAs), small interfering RNAs (siRNAs) 
and piwi-interacting RNAs (piRNAs) (Figure 3). They all share a role in gene 
silencing. However, their biogenesis and mechanism of action differ from each other. 
In addition to them, there are also other small non-coding RNAs, such as guide 
RNAs (gRNAs or sgRNAs) and Y RNAs (Figure 3). The Tryptanosoma parasite has 
a unique regulatory system for mitochondrial mRNA editing that involves gRNAs 
(Seiwert & Stuart, 1994). They are not expressed in humans, but the CRISPR-Cas9 
genome editing technology utilizes artificially made gRNAs in directing the nuclease 
activity to the target loci (reviewed in Nowak et al, 2016).  Y RNAs are evolutionary 
conserved (Wolin et al, 2013) and originally discovered in patients with lupus 
erythematosus complexed with the Ro60 auto-antigen (Lerner et al, 1981). They 
regulate the subcellular localization of Ro60 but there are also several reports 
supporting their role in the initiation of DNA replication (reviewed in Kowalski & 
Krude, 2015). 
miRNA genes are transcribed into precursor miRNAs (pri-miRNAs) mainly by 
RNA Polymerase II (RNA Pol II), but a small subset of miRNAs can be transcribed 
also by RNA Polymerase III (Lee et al, 2004; Borchert et al, 2006). The pri-miRNAs 
are further processed in the nucleus by an RNase III nuclease, Drosha-DGCR8 
complex into hairpin-shaped pre-miRNAs, which are then exported to the 
cytoplasm (Han et al, 2004). Finally, the pre-miRNAs are cleaved by another RNase 
III nuclease, Dicer-TRBD complex and the mature miRNA is incorporated with 
Dicer-TRBD and Argonaute proteins to form the functional gene silencing complex 
RISC (RNA-induced gene silencing complex) (Wang et al, 2009). The RISC complex 
is guided by a miRNA to the specific gene transcript based on sequence 
complementarity and it inhibits protein translation with or without mRNA 
degradation (reviewed in Stroynowska-Czerwinska et al, 2014). The miRNA genes 
are evolutionary conserved, although the animal and plant miRNAs differ in their 
sequences and processing (reviewed in Millar & Waterhouse, 2005). The mammalian 
miRNA genes are often clustered and located in the intronic or exonic areas within 
a protein or non-coding gene, or in rare cases miRNA genes can reside next to their 
own gene promoter (reviewed in Olena & Patton, 2010).  
Endogenous siRNAs are derived from long double-stranded RNAs (dsRNAs) 
and similarly to miRNAs they are processed in the cytoplasm by the Dicer-TRBD 
nuclease complex prior to forming the RISC complex (Hammond et al, 2000). In 
plants siRNAs present a natural defense mechanism against viral mRNAs (Hamilton 
& Baulcombe, 1999). Studies with Drosophila have shown that the endogenous 
siRNA pathway regulates for instance heterochromatin formation (Fagegaltier et al, 
2009) and embryo development (Lucchetta et al, 2009). In mouse oocytes, they have 
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been shown to regulate meiosis (Stein et al, 2015). The biological role of endogenous 
siRNAs in humans is not well understood, nevertheless the characterization of the 
siRNA pathway has led to the development of artificially made siRNAs that are 
widely used in gene silencing studies in vitro (reviewed in Mocellin & Provenzano, 
2004). Unlike miRNAs and siRNAs, piRNAs are derived from single-stranded RNA 
(ssRNA) and they are processed by a mechanism independent of RNAse III enzymes 
(reviewed in Le Thomas et al, 2014). The piRNA genes are clustered and they arise 
mainly from DNA regions with repetitive elements, such as retrotransposons 
(Brennecke et al, 2007). In Drosophila they are important mediators of transposable 
element silencing, a mechanism to protect genome integrity (reviewed in Aravin et 
al, 2007). In mammals, they are specifically expressed in germ-cells during 
spermatogenesis (Girard et al, 2006; Pantano et al, 2015), nevertheless their role in 
somatic cells is not yet well understood.  
2.2.4 Long non-coding RNAs   
Long non-coding RNAs (lncRNAs) are mainly transcribed by RNA Pol II and they 
undergo post-transcriptional processing, such as 5’-capping, splicing and 
polyadenylation (reviewed in Quinn & Chang, 2016). In this way they closely 
resemble mRNAs with the exception that they are not translated into proteins. As 
mentioned earlier, to distinguish them from small ncRNAs they are considered as 
non-coding RNAs larger than 200 nucleotides. Further classification into distinct 
lncRNA subgroups is commonly based on their structure or genomic location 
(Figure 3). Circular RNAs (circRNA) present a newly discovered group of lncRNAs 
that are structurally different from most lncRNAs. They are produced by back-
splicing of pre-mRNAs, resulting in covalently closed circular RNAs without 
polyadenylation (reviewed in Barrett & Salzman, 2016). Like many other lncRNAs 
they show very dynamic expression during differentiation. Despite most lncRNAs, 
expression of circRNAs seems to be conserved among mammals (reviewed in Barrett 
& Salzman, 2016). Linear lncRNAs can be categorized into four major types based 
on their genomic location (Figure 4). Long intergenic or intervening non-coding 
RNAs (lincRNAs) are transcribed from distinct loci, often from their own 
promoters, whereas intronic lncRNAs are transcribed from intronic region within a 
protein-coding gene (reviewed in Ma et al, 2013). Sense lncRNAs are transcribed 
from the sense strand of a protein-coding gene and they contain also exons from 
protein-coding genes (reviewed in Ma et al, 2013) (Figure 4). Natural antisense 
transcripts (NATs) are transcribed from the antisense strand of a protein-coding 
gene, overlapping either exonic or intronic regions (reviewed in Ma et al, 2013) 
(Figure 4). LncRNAs can be also transcribed from a bidirectional promoter, 
meaning that they are produced divergently from a protein-coding gene (Figure 4). 
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There is increasing evidence that divergent transcription is driving generation of new 
genes, and this could be an important source for emerging lncRNAs (reviewed in 
Kapusta & Feschotte, 2014). Moreover, divergent lncRNAs can have regulatory 
functions. Divergent transcription is relatively common for example in human and 
murine embryonic stem cells (Sigova et al, 2013). Moreover, expression of these 
lncRNA/mRNA pairs is coordinated during differentiation (Sigova et al, 2013), 
suggesting an important regulatory function for divergently expressed lncRNAs in 
embryonic development. There are also few examples of bidirectionally expressed 
lncRNAs functional in cancer (reviewed in Albrecht & Ørom, 2016).  
 
Figure 4. Classification of lncRNAs based on their genomic context. 
As the majority of the human genome is transcribed yielding thousands of 
lncRNA transcripts, it has also drawn a lot of speculation whether a part of the 
transcription is only “transcriptional noise” producing merely useless transcripts as 
a by-product of the process. However, the proportion of non-protein coding 
sequences in the genome grows as a function of developmental complexity, whereas 
the proportion of protein-coding sequences declines, indicating that the non-coding 
sequences have evolved for a reason (reviewed in Mattick, 2004). Supporting this 
hypothesis numerous studies have shown that ncRNAs, especially lncRNAs exhibit 
very cell and tissue type specific expression (Washietl et al, 2014; Wu et al, 2014; Guo 
et al, 2014) and sub-cellular localization (Zhang et al, 2014; Cabili e al, 2015). In 
addition, they are specifically expressed during processes like cellular development 
(reviewed in Devaux et al, 2015; Hassan et al, 2015), differentiation (reviewed in 
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Jeong & Goodell, 2016; Flynn & Chang, 2014) and stress response (Chang et al, 2014; 
reviewed in Place & Noonan, 2014; Turner et al, 2014). Additionally, it is becoming 
evident, that many lncRNAs are dysregulated in human diseases (Brunner et al, 2012; 
reviewed in Taft et al, 2010), which make them an attractive target for finding new 
biomarkers and therapeutic targets (reviewed in Sánchez & Huarte, 2013; Slaby et al, 
2017). The focus of the following chapters will be mainly on the regulation of 
lncRNAs and their cellular functions.  
2.2.4.1 Challenges in defining lncRNAs  
The research around lncRNAs is relatively young and new lncRNA genes are 
discovered from transcriptomic profiling, however their detailed characterization is 
challenging and time consuming. Many have questioned what is the true protein-
coding potential of lncRNAs. Frankly, it is not that straightforward to define. The 
most general approach to search for protein coding transcripts is to analyze the 
features of their open reading frames (ORFs), for example their length and 
phylogenetic conservation. Many lncRNAs do have ORFs, however most of them are 
shorter than ORFs of protein coding genes and they are located very closely upstream 
of the translation start site, predisposing transcripts to degradation by nonsense-
mediated decay (Niazi & Valadkhan, 2012). Overall, it is very unlikely for most 
lncRNAs to be translated into proteins or even short peptides based on the structure 
of their ORFs (Niazi & Valadkhan, 2012; Derrien et al, 2012). Another strategy is to 
look at the conservation of the transcripts and their ORFs by a sequence alignment-
based approach, such as Basic Local Alignment Tool (BLAST) (Chen et al, 2015) or 
phylogenetic assessment of codon substitution frequencies (PhyloCSF) (Lin et al, 
2011). Interestingly, lncRNAs are poorly conserved by their nucleotide sequence and 
they rarely have orthologs within different species but their gene promoters are 
almost as conserved as protein coding promoters (Pang et al, 2006; Derrien et al, 
2012; Washietl et al, 2014). In addition, lncRNAs seem to be under rapid 
evolutionary turnover (reviewed in Nitsche & Stadler, 2017).  
The challenge in using computational analyses when predicting protein coding 
capacity of a transcript is that they use different algorithms and based on the given 
criteria the results may vary. Therefore, it is more reliable to use additional methods 
beside the predictions based on the genomic features. Ribosome profiling is a 
powerful, deep-sequencing based technique to examine protein translation globally 
and in vivo (reviewed in Ingolia, 2014). In principle, the translating ribosomes are 
mapped with nucleotide resolution across the transcriptome based on the sequenced 
fragments that are occupied by ribosomes, so called ribosome footprints (reviewed 
in Ingolia, 2014). The translated ORFs defined by ribosome profiling can be used to 
identify new protein coding regions in the genome that may encode alternative 
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isoforms of known proteins or they might be short ORFs (sORFs) as a source for new 
peptides (reviewed in Brar & Weissman, 2015).  This method can be also combined 
with mass-spectrometric analysis to evaluate whether the defined ORFs are encoding 
peptides (Slavoff et al, 2013; Fritsch et al, 2012). 
Although most of the ribosome footprints are mapped to known protein coding 
areas, there are several reports where they have been found outside of these areas, 
indicating non-coding RNA translation (Ruiz-Orera et al, 2014; Chew et al, 2013; 
Ingolia et al, 2014). However, this does not always lead to a stable and functionally 
relevant polypeptide. Instead, the translational process itself might be regulatory. For 
example, translation of an upstream ORF (uORF) can inhibit translation of the 
downstream protein-coding ORF (reviewed in Somers et al, 2013). It has been also 
proposed that translated ncRNAs could be a source for new protein-coding genes 
through evolutionary selection (reviewed in McLysaght & Guerzoni, 2015). A large 
fraction of lncRNAs have been shown to associate with ribosomes in human and 
mouse, however their protein coding potential remains relatively low, indicating that 
ribosome association does not necessarily mean translation (Zeng et al, 2018). Some 
of these proteins are also misannotated as lncRNAs (Zeng et al, 2018). Sole lncRNA 
interaction with the ribosome can also have a regulatory function (reviewed in 
Pircher et al, 2014), as shown for ZNFX1 antisense RNA 1 (Hansji et al, 2016). 
Overall, it is challenging to study ncRNA translation and at least for now the debate 
around lncRNA translation remains (Ji et al, 2015; Guttman et al, 2013). 
2.2.4.2 Molecular mechanisms of lncRNAs 
There is a broad spectrum of functional mechanisms for lncRNAs. As single-
stranded RNA-molecules they can interact with DNA, RNA or proteins, making 
them very versatile regulators in the cell (reviewed in Wang & Chang, 2011). They 
have also unique secondary and tertiary structures important for mediating these 
interactions (reviewed in Blythe et al, 2016). Without the need for translation they 
can rapidly carry out their regulatory function, after which they can be quickly 
degraded. Their mechanism of action could be divided into four main types; signals, 
guides, decoys and scaffolds (Figure 5) (reviewed in Wang & Chang, 2011). Simply, 
they could be also grouped as lncRNAs functional either in the nucleus, mainly in 
mediating transcription (reviewed in Kaikkonen & Adelman, 2016) or in the 
cytoplasm in regulating post-transcriptional events (reviewed in Noh et al, 2018) 
(Figure 5).  
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Figure 5. Molecular functions of lncRNAs. In the nucleus lncRNAs can regulate epigenetic changes 
by decoying (a) or guiding (b) chromatin modifying complexes to specific genomic loci. LncRNAs can 
mediate chromosomal looping (c) by simultaneously binding to protein complexes or specific DNA-
elements and bringing them to close proximity. LncRNAs can inhibit gene transcription by binding to DNA 
and blocking the transcription factor binding site (d). Additionally, gene transcription can be activated or 
inhibited by lncRNAs guiding or decoying transcription factors (e). LncRNA binding to RNA polymerase 
can inhibit transcription (f). Alternative splicing can occur by lncRNA binding to mRNA and blocking the 
splice-site. LncRNAs can also recruit and guide splicing factors to the sites of transcription (g). In the 
cytoplasm lncRNAs can regulate mRNA stability directly by binding to mRNAs (h) or indirectly by binding 
to miRNAs (i) by complementary base-pairing. LncRNAs can be secreted to extracellular vesicles and 
exosomes allowing them to mediate intercellular signaling (j). Scaffold lncRNAs function by flexible 
lncRNA-protein binding and promote the assembly of active ribonucleoprotein complexes (k). Protein-
binding lncRNAs can also mediate intracellular translocation of proteins (l). 
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LncRNA expression is very dynamic, allowing a fast response to external stimuli. 
Specific lncRNA expression has been noted for instance in response to DNA-damage 
(Sánchez et al, 2014), growth factors (Li et al, 2013; Kambara et al, 2014), immune 
response (Carpenter et al, 2013) and circadian changes (Coon et al, 2012). 
Particularly in plants lncRNAs serve as specific signals for environmental changes 
(reviewed in Liu et al, 2015). Additionally, lncRNAs can be secreted into extracellular 
vesicles and exosomes, and delivered outside of the cell where they can exert their 
functions even at long-distance (Huang et al, 2013). Exosomal lncRNAs function as 
signals in cell-cell communication and they have been implicated in cancer as 
potential regulators of drug resistance, for instance (reviewed in Zhou et al, 2018). A 
recent study illustrates a mechanism for lncRNA DINOL (damage induced long 
noncoding RNA) as a signal for DNA damage (Schmitt et al, 2016). It is transcribed 
divergently from p53-responsive CDKN1A gene upon DNA damage and it binds to 
and stabilizes p53, promoting p53-dependent gene expression, cell cycle arrest and 
apoptosis in response to DNA damage (Schmitt et al, 2016). In addition to DINOL, 
many other DNA damage inducible lncRNAs are characterized, such as NORAD 
(non-coding RNA activated by DNA damage; LINC00657) and PANDAR (promoter 
of CDKN1A antisense DNA damage activated RNA) (Lee et al, 2016; Hung et al, 
2011).  
Several lncRNAs have been shown to regulate gene expression by epigenetic 
mechanisms (reviewed in Marchese & Huarte, 2014). In principle, a lncRNA can 
bind to and guide gene regulatory complexes, such as gene silencing PRC2-complex, 
or gene activating complexes to a specific loci in the genome and bind to DNA by 
RNA:DNA heteroduplex or by  forming a stable RNA:DNA:DNA triplex (reviewed 
in Wang & Chang, 2011). Guide lncRNAs can function in cis or trans, meaning that 
they can mediate changes in gene expression of the neighboring gene (cis) or 
distantly located gene (trans) (reviewed in Roberts et al, 2014).  
In contrast to a guide lncRNA the functional mechanism of a decoy involves 
lncRNA binding to a gene regulator in order to negatively affect its function. In other 
words it prevents the effector molecule from binding to its target (reviewed in Wang 
& Chang, 2011). An interesting example of a decoy lncRNA is growth arrest-specific 
5 (GAS5; NCRNA00030). It accumulates in growth-arrested cells, for example after 
serum starvation and it functions as a repressor for glucocorticoid receptor (GR) 
(Kino et al, 2010). Mechanistically it interacts with the DNA-binding domain of the 
GR and inhibits the receptor from binding to its target regulatory regions of the 
glucocorticoid-responsive genes (Kino et al, 2010). Another example of a decoy 
lncRNA is so called miRNA sponge. The competitive endogenous RNA (ceRNA) 
hypothesis suggests that RNA-transcripts can decoy miRNAs in case they have 
complementary miRNA-binding sites with the target mRNA (reviewed in Thomson 
& Dinger, 2016). Therefore, lncRNAs can regulate for example mRNA stability by 
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competing miRNA targeting (reviewed in Bayoumi et al, 2016). This seems to be a 
central function especially for circRNAs, however it remains to be elucidated how 
the endogenously expressed miRNA sponges work in the physiological context 
(reviewed in Thomson & Dinger, 2016). In addition to miRNA targeting there are 
also lncRNAs which can bind directly to mRNA and modulate its stability (Gong & 
Maquat 2011; Gong et al, 2015; Faghihi et al, 2008). The previous examples of guides 
and decoys demonstrate how lncRNAs can regulate gene transcription indirectly by 
interacting with gene regulatory complexes or miRNAs. It is important to note that 
lncRNAs can inhibit transcription directly as well. A few lncRNAs have been shown 
to directly bind to RNA Pol II leading to transcription inhibition (Espinoza et al, 
2004; Mariner et al, 2008). Additionally, lncRNA binding to genomic DNA may 
inhibit pre-initiation complex assembly and gene transcription (Martianov et al, 
2007). 
Scaffold lncRNAs are lncRNAs that are interacting with proteins or RNP 
complexes bringing together different effectors and allowing proper organization of 
a functionally active RNP complex (reviewed in Wang & Chang, 2011). In this way 
lncRNAs are able to modulate a variety of different regulatory functions in the cell 
(reviewed in Geisler & Coller, 2013). One well-studied example of a scaffold lncRNA 
is HOX antisense transcript RNA (NCRNA00072), better known as HOTAIR. It 
simultaneously binds to PRC2-complex and another chromatin modifying complex, 
LSD1/coREST/REST, to mediate gene silencing (Tsai et al, 2010). Another 
scaffolding function for HOTAIR has been shown, where it associates with E3 
ubiquitin ligases and their respective substrates, facilitating degradation of the target 
transcripts (Yoon et al, 2013). There is also evidence for lncRNAs in organizing the 
nuclear structure. Nuclear Enriched Abundant Transcript 1 (NEAT1; LINC00084) 
is a classic example of a lncRNA working as an assembly platform required for 
nuclear paraspeckle formation and maintenance (Mao et al, 2011). In this case 
NEAT1 works as a scaffold for recruiting proteins to assemble paraspeckles at 
NEAT1 gene loci. It has been also proposed that there might be several other 
lncRNAs whose transcription may serve as a mark for nuclear proteins to pull the 
genomic DNA into new positions, therefore changing the 3D organization of the 
genome (Melé & Rinn, 2016). 
2.2.4.3 LncRNAs in cancer 
A lot of effort has been done in characterizing the driver mutations in the genes that 
are regulating fundamental signaling pathways, such as p53 and Myc (reviewed in 
Garraway & Lander, 2013). For example, even a small change in the DNA such as a 
point mutation or single-nucleotide polymorphism (SNP) can alter the amino acid 
composition of a signaling protein disrupting its function. Similarly, SNPs can affect 
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lncRNA structure and functionality (Lai et al, 2013; Tan et al, 2017; reviewed in Gao 
& Wei, 2017). Moreover, a significant part of mutations reside in the non-coding 
regions of the genome which may affect gene expression due to alterations in gene 
regulatory areas, but lncRNA expression can be affected as well (reviewed in 
Khurana et al, 2016; Schmitt & Chang, 2016; Gao & Wei, 2017). In this regard it is 
not surprising that several cancer-related lncRNAs are transcribed from loci that are 
associated with increased cancer risk (reviewed in Cheetham et al, 2013; Gao & Wei, 
2017). 
Deregulation of lncRNAs has been noted in many human cancers and their 
functional importance in cancer is emerging (reviewed in Gutschner & Diederichs, 
2012; Schmitt & Chang, 2016; Lin & Yang, 2018). Similarly to proteins, lncRNAs are 
found to be important regulators at different stages of tumorigenesis; regulators of 
proliferative signaling, angiogenesis, invasion, epigenetics, et cetera (reviewed in 
Gutschner & Diederichs). Differential lncRNA expression in cancer could be utilized 
by using them as prognostic and diagnostic markers (reviewed in Qi et al, 2016; Silva 
et al, 2015). LncRNAs have been implicated in drug resistance of cancer cells 
(reviewed in Deng et al, 2016). Therefore a specific lncRNA expression signature 
could be used to help to distinguish patients with good chemo-response and drug 
resistance. Moreover, a deeper understanding of their functional mechanisms may 
provide novel lncRNA-targeted therapies for cancer treatment (reviewed in Leucci, 
2018; Slaby et al, 2017; Sánchez & Huarte, 2013). Here, I will describe a few examples 
of functionally relevant lncRNAs in cancer. 
H19 (LINC00008) is one of the most extensively studied lncRNAs today, 
originally found in the 1990s and it presents one the earliest clues of functional 
lncRNAs, even though the definition did not exist at the time (Brannan et al, 1990). 
It was first identified as a highly expressed RNA in mouse embryo, mutually 
imprinted with its neighboring insulin-like growth factor 2 gene, IGF2 (Brannan et 
al, 1990). Several lines of evidence support a tumorigenic role for H19 (reviewed in 
Yoshimura et al, 2018), however it may act differentially depending on the cell 
developmental stage (reviewed in Raveh et al, 2015). Firstly, it is a source for miR-
675, which is expressed from the first exon of H19 gene (Cai & Cullen, 2007). This 
miRNA functions as oncogene in many malignancies by targeting important 
regulators, such as tumor-suppressive retinoblastoma protein (Rb) (reviewed in 
Raveh et al, 2015). It has been also implicated in EMT by targeting several EMT-
markers (Matouk et al, 2014; Kim et al, 2014). H19 can also decoy miRNAs, such as 
the let-7 miRNAs (Kallen et al, 2013). Secondly, there seems to be a link between H19 
and p53 regulation. H19 expression is repressed by p53 (Dugimont et al, 1998), but 
under hypoxic stress H19 expression is induced in p53-impaired cells (Matouk et al, 
2010). Moreover, H19 has been shown to regulate polyploidy (Shoshani et al, 2012). 
For example, when cells are in unstable state due to impaired p53 function H19 
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expression is induced, which prevents cells becoming polyploid (Ravid et al, 2014). 
By resisting polyploidy-mediated growth arrest H19 has an advantage to accelerate 
uncontrolled cell proliferation, which further increases accumulation of DNA-
mutations (reviewed in Raveh et al, 2015). Overall, H19 is regulating tumor 
progression on many different levels in a complex but coordinated manner 
(reviewed in Raveh et al, 2015). 
MALAT1 (metastasis associated lung adenocarcinoma transcript 1) is another 
well characterized lncRNA involved in various cellular processes and implicated as a 
tumor promoting factor in many cancers (reviewed in Zhang et al, 2017). MALAT1, 
also known as NEAT2 (LINC00047), is transcribed from the same gene locus as 
NEAT1, a functional scaffolding lncRNA in the nuclear paraspeckles (Mao et al, 
2011). However, there is no significant homology between them (Hutchinson et al, 
2007). In fact, despite their similar localization in the nuclear speckles, they have 
distinct functions. As indicated by its name, MALAT1 was found to be highly 
enriched in metastasis associated non-small cell lung cancer (NSCLC) tumors when 
compared to non-metastasizing tumors (Ji et al, 2003). Later on, its elevated 
expression was noted in hepatocellular carcinoma (Lin et al, 2007), endometrial 
stromal sarcomas (Yamada et al, 2006) and many other human cancers (reviewed in 
Gutschner et al, 2013). The primary, nuclear-localizing MALAT1 transcript is 
processed so that the poly(A) tail is cleaved, generating a very stable triple-helix 
structure to the 3’end of the RNA (Wilusz et al, 2008; Brown et al, 2014). This 
structure protects MALAT1 from exonucleolytic degradation, but it may have 
additional functional role in nuclear transport and translation (reviewed in Wilusz, 
2016). MALAT1 has shown to regulate alternative splicing by interacting with pre-
mRNA splicing factors, such as SRSF1, and controlling their spatial distribution to 
nuclear speckles (Tripathi et al, 2010). MALAT1 knockdown was shown to reduce 
alternative splicing of oncogenic isoforms of previously reported SRSF1 target genes 
(Malakar et al, 2017). In addition, a recent study elucidates how MALAT1 is 
aberrantly delocalized from the nuclear speckles by a SRSF1-ID4-mutp53 protein 
complex (Pruszko et al, 2017). This enables MALAT1 recruitment on vascular 
endothelial growth factor A (VEGFA) pre-mRNAs and production of pro‐
angiogenic VEGFA isoforms in breast cancer, supporting the role of MALAT1 in 
alternative splicing (Pruszko et al, 2017). Interestingly, Malat1 gene depletion results 
in perfectly viable mice with no apparent abnormalities, but the pre-mRNA splicing 
or the localization of nuclear speckle components is not affected in these mice 
(Nakagawa et al, 2012; Zhang et al, 2012). It seems that MALAT1 may not be 
regulated similarly in mice and humans, especially in a normal physiological stage. 
Nevertheless, it may acquire a specific function during tumorigenesis. 
MEG3 (maternally expressed 3; LINC00023) is a lncRNA functioning as tumor 
suppressor (reviewed in Balas & Johnson, 2018; Zhou et al, 2012). It is widely 
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expressed in normal human tissues and the loss of MEG3 expression due to 
epigenetic silencing of MEG3 gene promoter is reported in several cancer types (Gao 
et al, 2017; Zhang et al, 2010; Anwar et al, 2012; Benetatos et al, 2008; Sheng et al, 
2014). Similarly to H19, MEG3 has been shown to bind to chromatin modifying 
protein complexes, such as PRC2 to regulate gene expression (Mondal et al, 2015). 
One of these targets is transforming growth factor beta (TGF-β) pathway, which is 
strongly related to EMT regulation (Mondal et al, 2015). Additionally, MEG3 has 
been shown to bind and stabilize p53 (Zhu et al, 2015). It also activates p53 by 
repressing expression of MDM2 proto-oncogene, which is a known E3 ubiquitin 
ligase mediating p53 degradation (Zhou et al, 2007). In several studies MEG3 re-
expression has been shown to inhibit tumor growth in vitro and in vivo (Jin et al, 
2018; Xu et al, 2018; Zhang et al, 2017). MEG3 gene deletion results in perinatal death 
in mice, indicating a crucial role for MEG3 in embryonic development (Takahashi 
et al, 2009). Therefore, studying MEG3 function in tumorigenesis in vivo seems 
challenging. By studying mouse embryos Takahashi and colleagues showed that 
teratomas derived from meg-/+ embryos exhibited hypertrophic growth compared to 
the control group (Takahashi et al, 2015). Additionally, a study by Gordon and 
colleagues indicates that MEG3 has a regulatory function in brain vascularization 
and it may inhibit tumorigenesis by suppressing angiogenesis (Gordon et al, 2010). 
Overall, these results implicate a pivotal role for MEG3 functioning as a tumor 
suppressor.  
2.2.5 Importance of lncRNAs in cutaneous biology 
2.2.5.1 Functionally relevant lncRNAs in the skin 
Several lncRNAs have been characterized in different skin malignancies, which will 
be discussed more closely in the next chapters. However, not much is known about 
the role of lncRNA in normal skin homeostasis. Environmental stress can specifically 
induce or repress lncRNA expression, shown in several human cell lines (Sánchez et 
al, 2014; Chang et al, 2014; Place & Noonan, 2014; Turner et al, 2014) and the same 
applies to skin. UV-irradiation, especially the UVB with higher tendency for skin 
cancer formation, has shown to affect the transcriptional profile of lncRNAs in 
normal keratinocytes (Kim et al, 2017), fibroblasts (Li et al, 2018) and melanocytes 
(Zeng et al, 2016). Moreover, UVA and UVB regulate expression of different set of 
lncRNAs in keratinocytes (Yo & Rünger, 2017), which highlights the differential 
cellular response to UVA and UVB. It is well known that the most effective way to 
prevent skin cancer is to avoid exposure to sun UV-light. However, recent findings 
strongly support cancer protecting role also for vitamin D (reviewed in Reichrath et 
al, 2017). Vitamin D signaling affects lncRNA expression as well (Jiang & Bikle, 
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2014). Interestingly, keratinocytes lacking vitamin D receptor show a distinct 
lncRNA expression pattern with increased expression of oncogenic lncRNAs and 
decreased expression of tumor-suppressive lncRNAs (Jiang & Bikle, 2014), 
supporting the cancer protecting role for vitamin D signaling in skin. Overall, these 
expression profiling studies may give important clues of the protective roles of 
certain lncRNA against skin cancer progression. On the other hand, some of these 
lncRNAs may function as tumor-promoters.  
To provide more insight to the functional mechanisms for lncRNAs in epidermal 
regulation, a few examples will be discussed here in detail. DANCR (differentiation 
antagonizing non-protein coding RNA; KIAA0114), as implied by its name it is a 
differentiation antagonizing lncRNA. In the study by Kretz and colleagues (Kretz et 
al, 2012) primary human keratinocytes were treated with calcium to induce 
differentiation and cells were subjected to RNA sequencing. Differentially expressed 
transcripts were compared with chromatin signatures to explore their transcription 
dynamics during differentiation. They found DANCR to be suppressed during 
terminal differentiation and it was also downregulated in the basal layer of mature 
human epidermis compared to the suprabasal layer (Kretz et al, 2012). Silencing of 
DANCR expression in progenitor keratinocytes led to induction of genes associated 
with epidermal differentiation, such as filaggrin, loricrin, involucrin, and S100 
calcium-binding proteins A8 and A9 (Kretz et al, 2012). Moreover, silencing of 
DANCR in organotypic epidermal tissue resulted in expression of differentiation 
proteins in the basal layer, where they are not normally expressed. These results 
implicate that DANCR is required to maintain epidermal progenitor cells in 
undifferentiated state. Further study by the same group (Lopez-Pajares et al, 2015) 
found DANCR to be a negative regulator of MAF and MAFB transcription factors, 
which are important regulators of differentiation in various cell types. DANCR 
represses their expression epigenetically by guiding a chromatin modifying protein 
complex to their gene promoters. Subsequent studies have shown similar function 
for DANCR for instance in osteoblast differentiation (Zhu & Xu, 2013). In addition 
to DANCR, two other lncRNAs, LINC00941 and BLNCR (beta1-adjacent long non-
coding RNA), have been recently implicated in keratinocyte differentiation (Ziegler 
et al, 2019; Tanis et al, 2019). LINC00941 represses keratinocyte differentiation by 
antagonizing the function of SPRR5, a previously uncharacterized molecule which is 
a positive regulator of keratinocyte differentiation (Ziegler et al, 2019). 
Downregulation of BLNCR expression was noted during keratinocyte differentiation 
and transcription of BLNCR was shown to be activated by p63 and AP-1 
transcription factors (Tanis et al, 2019). BLNCR expression was co-regulated with 
ITGB1 (integrin beta 1), which is located adjacent to BLNCR and transcribed in the 
opposite direction. The authors of this study propose that the loss of BLNCR 
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expression is an early event when keratinocytes lose their proliferative capacity and 
proceed to terminal differentiation (Tanis et al, 2019).  
In contrast to DANCR, TINCR (terminal differentiation-induced ncRNA; 
LINC00036) promotes epidermal differentiation. Kretz and colleagues identified 
TINCR among the most highly expressed lncRNAs in differentiating keratinocytes 
and specifically enriched in the differentiated layers of human epidermis (Kretz et al, 
2013). They noted that formation of the epidermal barrier was disturbed in TINCR-
depleted organotypic human epidermal tissue (Kretz et al, 2013). To support this 
observation, transcriptome profiling revealed several epidermal barrier formation –
related genes to be regulated by TINCR. The functional mechanism of TINCR was 
examined in two ways. First, TINCR-binding RNAs were detected by hybridizing 
biotinylated TINCR transcripts in keratinocytes, followed by RNA pull-down and 
deep sequencing. TINCR-interacting genes were enriched with differentiation-
related genes, suggesting a post-transcriptional mechanism for regulation by 
TINCR. A specific 25-nucleotide motif was found to be necessary for the RNA-
mRNA interaction. Next, TINCR protein targets were examined by using a 
microarray analysis with fluorescently labeled TINCR transcripts (Kretz et al, 2013). 
The strongest signal for TINCR binding was detected by staufen double-stranded 
RNA binding protein 1 (STAU1), a well-studied RNA-binding protein. Interestingly, 
there was a significant overlap between gene expression profiles of TINCR- and 
STAU1-depleted epidermis, indicating that they are both required for epidermal 
differentiation. In addition, they seem to function by stabilizing mRNAs rather than 
targeting them to degradation. In contrast to DANCR, TINCR was identified as a 
positive upstream regulator for MAF and MAFB transcription factors by stabilizing 
their mRNA stability (Lopez-Pajares et al, 2015). In another study TINCR was shown 
to stabilize mRNA of calmodulin like 5 (CALML5), an epidermal differentiation 
promoting protein enriched in the differentiated layers of human epidermis (Sun et 
al, 2015). Altogether, these observations implicate TINCR as a key mediator in 
driving epidermal differentiation. Similarly to TINCR, a recently identified novel 
lncRNA SMRT-2 (SCC misregulated transcript 2) was shown to be induced during 
keratinocyte differentiation and SMRT-2 knockdown resulted in altered gene 
expression signature, which may occur via transcriptional regulators KLF4 (Kruppel 
Like Factor 4) and ZNF750 (Zinc Finger Protein 750) (Lee et al, 2018).   
2.2.5.2 Involvement of lncRNAs in skin disorders 
LncRNA expression profiles are explored in several skin disorders, for instance in 
abnormal scarring (Liang et al, 2015; Li et al, 2015; Sun et al, 2017; Tu et al, 2018), 
psoriasis (Ahn et al, 2016; Tsoi et al, 2015; Gupta et al, 2016) and actinic dermatitis 
(Lei et al, 2017). Interestingly, there are also few lncRNAs associated with rare genetic 
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syndromes with cutaneous defects, such as Beckwith–Wiedemann and McCune–
Albright syndromes (reviewed in Wan & Wang, 2014). There is still a lack of detailed 
characterization of the functionally relevant lncRNAs in many of these disorders. 
However, one good example of a psoriasis associated lncRNA is described here in 
more detail. 
LncRNA PRINS (psoriasis susceptibility-related RNA gene induced by stress; 
NCRNA00074) is the first lncRNA characterized in psoriasis (Sonkoly et al, 2005). 
Its expression was higher in the uninvolved epidermis of psoriatic patients compared 
with healthy epidermis. It was specifically induced in HaCaT cells after serum 
starvation, UVB-irradiation, viral infection or translational inhibition, suggesting a 
protective role for PRINS in cellular stress response (Sonkoly et al, 2005). Further 
studies by the same group revealed two target genes for PRINS – G1P3 (or interferon 
alpha inducible protein 6, IFI6) and nucleophosmin 1 (NPM1) (Szegedi et al, 2010 
and 2012). PRINS was shown to positively regulate G1P3, which was found 
remarkably abundant in psoriatic lesional tissue, indicating a possible role for G1P3 
in the pathogenesis of the disease (Szegedi et al, 2010). NMP1 was found to physically 
interact with PRINS, which was shown by in vitro pull-down assay and by examining 
their expression patterns in the epidermis (Szegedi et al, 2012). Induction of PRINS 
by UVB was shown in the previous study (Sonkoly et al, 2005). Interestingly, NPM1 
is also known to be regulated by UVB in fibroblasts and cancer cells, resulting in 
nucleoplasmic translocation of the nucleolar NPM1. Here, NPM1 translocation was 
inhibited in PRINS-depleted keratinocytes after UVB treatment, indicating that by 
physically interacting with NPM1 PRINS is modulating its intracellular shuttling 
(Szegedi et al, 2012). In addition to these functional findings for PRINS, a recent 
study shows that PRINS has an important role in keratinocyte innate immune 
response in regulating cytokine expression (Danis et al, 2017), highlighting the 
association with PRINS in psoriasis susceptibility.  
The role of lncRNAs in skin wound healing is largely unknown, even though 
functions of miRNAs are widely studied in wound healing (reviewed in Herter & Xu 
Landén, 2017). LOC100130476 and LOC105372576 are recently identified lncRNAs, 
both observed with reduced expression levels in chronic non-healing wounds 
compared to normal skin (Herter et al, 2018; Li et al, 2019). Induced expression of 
LOC100130476 led to restriction of inflammatory chemokine production and 
improved wound healing and based on these findings it was named WAKMAR2, 
wound and keratinocyte migration associated lncRNA 2 (Herter et al, 2018). 
LOC105372576, named WAKMAR1 (wound and keratinocyte migration-associated 
lncRNA 1) was shown to regulate keratinocyte motility through E2F1 transcription 
factor (Li et al, 2019). Similarly to WAKMAR2, induced expression of WAKMAR1 
resulted in increased keratinocyte migration and re-epitelization of human ex vivo 
wounds (Li et al, 2019). Together, WAKMAR1 and WAKMAR2 deficiency may be 
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associated with the pathogenesis of chronic wounds. In another study MALAT1 was 
shown to stimulate healing of ischemic wounds in vivo by treating the wounds with 
conditioned media enriched in MALAT1-containing exosomes (Cooper et al, 2018). 
The same treatment increased migration of human dermal fibroblasts in vitro, 
whereas treatment with MALAT1-depleted exosomes decreased their migration 
(Cooper et al, 2018). Similarly to MALAT1, exosomal delivery of lncRNA H19 was 
shown to improve angiogenesis and healing of diabetic wounds in a diabetic rat 
model (Tao et al, 2018). Interestingly, even though MALAT1 and H19 are mainly 
linked to cancer progression, they may be used therapeutically to improve chronic 
wound closure. Topically applied mevastatin, a cholesterol-reducing agent, has been 
shown to promote wound healing in vivo by inducing epithelialization and 
keratinocyte-driven angiogenesis (Sawaya et al, 2018). Cholesterol is synthetized in 
the epidermis and it is a precursor for cortisol, which is a negative regulator of wound 
healing acting via glucocorticoid receptor (GR) (Vukelic et al, 2011). Here, 
mevastatin was shown to block GR activation and cortisol synthesis by inhibiting c-
myc (Sawaya et al, 2018). GAS5 lncRNA, a known GR repressor (Kino et al, 2010) 
was strongly induced by mevastatin in diabetic foot ulcers in vivo and GAS5 
overexpression in spontaneously immortalized keratinocyte cells (HaCaT) led to c-
myc inhibition (Sawaya et al, 2018). Collectively, these lncRNAs may work as 
potential therapeutic targets in treating chronic non-healing wounds. 
2.2.5.3 Emerging roles of lncRNAs in skin cancers  
As mentioned previously, lncRNA expression is altered in the skin after UV-
irradiation (Kim et al, 2017; Li et al, 2018; Zeng et al, 2016; Yo & Rünger, 2017), 
indicating that some of them might have a protective role in skin cancer formation. 
In some instances, lncRNA expression or regulation may be disturbed for example 
due to genetic alteration in cancer. This is very likely particularly in skin cancers, as 
they are highly susceptible for UV-induced mutations that arise early in skin 
carcinogenesis (reviewed in Chen et al, 2014). Many skin cancer associated gene 
mutations are characterized, such as p53, however the impact on lncRNA regulation 
by UV-induced mutations is not known.  
BRAF is a well-studied serine/threonine kinase which is mutationally activated 
in many human cancers, including melanoma (reviewed in Holderfield et al, 2014). 
Paradoxically, the majority of BRAF mutations arise in skin areas without chronic 
sun-induced damage (Curtin et al, 2005). In an intriguing study by Flockhart and 
colleagues transcriptome profiles between normal melanocytes and BRAF-mutant 
melanomas were compared to identify new BRAF-oncogene targeted genes in 
melanoma progression (Flockhart et al, 2012). They discovered lncRNA BANCR 
(BRAF-activated non-protein coding RNA) as one of the most highly induced 
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transcripts by oncogenic BRAF, and it was shown to regulate melanoma cell 
migration (Flockhart et al, 2012). Another fine example of a lncRNA deregulated by 
genetic alteration is SAMMSON, survival associated mitochondrial melanoma 
specific oncogenic non-coding RNA (LINC01212). Leucci and colleagues discovered 
the SAMMSON gene co-amplified with a focal amplification of chromosome 3p13-
3p14, a known gene alteration which is associated with a poor prognosis in a subset 
of melanomas (Leucci et al, 2016). This area encompasses MITF gene 
(microphthalmia-associated transcription factor) approximately 30 kilobases 
upstream of SAMMSON and it is an important regulator of melanocyte survival and 
pigment production. However, when amplified or mutated, MITF has an oncogenic 
role in melanoma progression (Garraway et al, 2005; Yokoyama et al, 2011). 
SAMMSON expression was positively correlated with melanoma malignancy and 
copy number gain (Leucci et al, 2016). Furthermore, it was shown to promote 
melanoma growth and survival via mitochondrial p32 protein (Leucci et al, 2016). 
There was no correlation in MITF and SAMMSON expression levels in clinical 
melanoma samples, and MITF expression was not affected in cis by SAMMSON 
(Leucci et al, 2016). Therefore, even though SAMMSON and MITF are not co-
regulated, the MITF-SAMMSON amplicon may be beneficial for transforming 
melanocytes due to their combined, oncogenic regulatory role in melanoma.  
While many lncRNAs have been characterized in melanoma (reviewed in Richtig 
et al, 2017) the role of lncRNAs in non-melanoma skin cancers is not well 
understood. A literature search revealed a few lncRNAs implicated in non-
melanoma skin cancer, such as TINCR and SMRT-2 (Table 1). They are both 
differentiation promoting lncRNA in keratinocytes and decreased expression of 
TINCR and SMRT-2 was noted in human cSCC specimens (Kretz et al, 2013; Lee et 
al, 2018). Additionally, a notable decrease in TINCR expression was reported in 
murine DMBA/TPA-induced cSCC tumors compared to normal skin (Ponzio et al, 
2017). SMRT-2 expression was shown to be markedly suppressed also in Ras-driven 
human organotypic neoplasia, suggesting a tumor-suppressive role for SMRT-2 in 
cSCC (Lee et al, 2018). TINCR and SMRT-2 may function as tumor-suppressive 
lncRNAs in cSCC, especially as lack of differentiation is associated with poor 
prognosis and a risk factor for metastatic cSCC (reviewed in Kallini et al, 2015). 
Based on the literature LINC00319, LINC00520, LINC01048 and MALAT1 are the 
only functionally studied lncRNAs in human cSCC (Li et al, 2018; Mei & Zhong, 
2019; Chen et al, 2019; Zhang et al, 2019). In addition, a novel lncRNA transcript, 
AK144841 found in mouse DMBA/TPA-induced cSCC may present a novel tumor 
promoter (Ponzio et al, 2017), however its contribution to human cSCC remains to 
be elucidated. Of note, none functionally characterized lncRNAs in basal cell 
carcinoma (BCC) were found. LincRNA-p21 is highly inducible by UVB in human 
and mouse keratinocytes and in mouse skin in vivo (Hall et al, 2015). Moreover, the 
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transcriptional response was shown to be p53-dependent. LincRNA-p21 is an 
important regulator of UVB-induced apoptosis in keratinocytes (Hall et al, 2015). 
Interestingly, both lincRNA-p21 expression and UVB-induced apoptosis were 
significantly inhibited in mouse epidermis harboring a mutation in a single p53 allele 
(Hall et al, 2015). These results indicate a protective role for lincRNA-p21 in skin 
carcinogenesis. 
Table 1. Long non-coding RNAs implicated in keratinocyte cancers. 
LncRNA Expression Function Reference 
TINCR Downregulated in cSCC Controls human epidermal 
differentiation by stabilization of 
differentiation mRNAs 
Kretz et al, 
2013 
SMRT-2 Downregulated in cSCC Mediates keratinocyte differentiation  Lee et al, 
2018 
LINC00319 Upregulated in cSCC Regulates cell growth, migration, 
invasion and apoptosis by miR-1207-
5p-mediated regulation of cyclin-
dependent kinase 3 
Li et al, 2018 
LINC00520 Downregulated in cSCC Inhibits cSCC progression by 
targeting EGFR and PI3K/AKT 
signaling pathways 
Mei & Zhong, 
2019 
LINC01048 Upregulated in cSCC Interacts with TAF15 transcription 
factor to induce YAP1 transcription 
and tumorigenic function via Hippo 
signaling pathway 
Chen et al, 
2019 
MALAT1 Upregulated in cSCC Positively regulates EGFR protein 
expression via c-MYC and KTN1 
Zhang et al, 
2019 
lincRNA-p21 Induced in mouse and 
human keratinocytes by 
UVB 
Tumor suppressive role in triggering 
UVB-induced apoptotic death 
Hall et al, 
2015 
AK144841 Induced in mouse 
DMBA/TPA-induced 
cSCC 
Downregulates several anticancer 
and cell differentiation genes in 
mouse 
Ponzio et al, 
2017 
H19,            
Hottip,      
Nespas, 
mHOTAIR, 
Malat1,           
SRA 
Upregulated in vitamin D 
receptor (VDR) deleted 
mouse keratinocytes and 
epidermis 
Potential oncogenes in skin cancer 
progression 
Jiang & 
Bikle, 2014 
Kcnq1ot1, 
lincRNA‐p21, 
Foxn2‐as,       
Gtl2‐as,         
H19‐as 
Inhibited in VDR-deleted 
mouse keratinocytes and 
epidermis 
Potential tumor suppressors in skin 
cancer formation 
Jiang & 
Bikle, 2014 
H19,       
CASC15,    
SPRY4-IT 
Upregulated in BCC Potential oncogenes in BCC Sand et al, 
2016 
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3 Aims of the Study 
1. To investigate the role of deregulated lncRNAs in cSCC and to elucidate their 
role in cSCC progression. The main objective is to find and characterize new 
biomarkers for evaluating the risk of progression and metastasis of cSCC and 
identify novel therapeutic targets for recurrent and metastatic cSCC. (I) 
2. To investigate the functional role of lncRNA PICSAR in cSCC progression. 
(II) 
3. To investigate the role of lncRNA PRECSIT in cSCC progression. (III) 
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4 Materials and Methods 
4.1 Ethical issues (I, II, III) 
The use of normal skin and tumor samples was approved by the Ethics Committee 
of the Hospital District of Southwest Finland. A written informed consent was given 
from all the participants and the study was performed with the permission of Turku 
University Hospital according to the Declaration of Helsinki. The experiments with 
mice were carried out with the permission of the State Provincial Office of Southern 
Finland. 
4.2 Cells and tumor samples 
4.2.1 Normal human epidermal keratinocytes (I, III) 
Normal human epidermal keratinocytes (NHEKs) were established from skin of 
healthy individuals undergoing mammoplasty (Farshchian et al, 2011). NHEK-PC 
was purchased from PromoCell (Heidelberg, Germany). The HaCaT cell line was 
kindly provided by Dr. Norbert E. Fusenig (Deutsches Krebsforschungszentrum, 
Heidelberg, Germany). NHEKs and HaCaT cells were cultured as previously 
described (Riihilä et al, 2014; Farshchian et al, 2015). 
4.2.2 Human cSCC cell lines (I, II, III) 
Human primary (n = 5; UT-SCC-12A, UT-SCC91, UT-SCC105, UT-SCC111 and 
UT-SCC118) and metastatic (n = 3; UT-SCC7, UT-SCC59A and UT-SCC115) cSCC 
cell lines were established from surgically removed SCCs of the skin in Turku 
University Hospital and cultured as previously described (Riihilä et al, 2014). The 
authenticity of the cell lines has been verified by short tandem repeat profiling 
(Farshchian et al, 2017b). To determine the p53 mutational status of cSCC cells TP53 
single-nucleotide variants were examined with the Integrative Genomics Viewer 2.3 
software (https://software.broadinstitute.org/software/igv/) (Robinson et al, 2011) 
using the RNA-seq data of cSCC cells (Farshchian et al, 2017a; GSE66412) (III, 
Supplementary Figure S1 and Supplementary Table S1). 
Materials and Methods 
 47 
4.2.3 Tissue samples of cSCC tumors and normal skin (I) 
Tissue samples from primary cSCC tumors were collected from surgically 
removed tumors in the Turku University Hospital (Farshchian et al, 2011). 
Normal skin tissue samples were collected from the upper arm of healthy 
volunteers during a mammoplasty operation. Total RNA was extracted from 
tissue samples using RNeasy mini kit (Qiagen, Germantown, MD) and subjected 
for qRT-PCR analysis. 
4.2.4 Tissue microarrays (I, III) 
Tissue microarrays consisting of paraffin-embedded and formalin-fixed samples 
from normal sun-protected skin (n = 10), seborrheic keratosis (n = 26), actinic 
keratosis (n = 50), cSCC in situ (n = 25), and invasive cSCC (n = 81) were generated 
from the archival paraffin blocks from the Department of Pathology, Turku 
University Hospital (Riihilä et al, 2015; Farshchian et al, 2015). 
4.3 Antibodies 
The following antibodies used in the original publications (I-III) are listed in Table 
2 (WB, Western blot; IHC, immunohistochemistry; FC, flow cytometry; IFM, 
immunofluorescence microscopy). 
Table 2. Antibodies used in the original publications. 
 Antigen Catalog no. Supplier Method 
I pERK1/2 9101 Cell Signaling Technology, Beverly, MA WB 
I ERK1/2 9102 Cell Signaling Technology WB 
I DUSP6 sc-28902 Santa Cruz Biotechnology, Dallas, TX WB 
I p38α 05-454 Thermo Fisher Scientific, Fremont, CA WB 
I p38δ sc-7585 Santa Cruz Biotechnology WB 
I pCREB 9191 Cell Signaling Technology WB 
I Ki-67 (MIB-1) M7240 Agilent Technologies, Santa Clara, CA IHC, WB 
II Integrin α2 555668 BD Biosciences, San Jose, CA FC 
II Integrin α5 555615 BD Biosciences FC 
II Integrin β1 553715 BD Biosciences FC 
II Integrin α2 MCA2025 Bio-Rad, Hercules, CA IFM 
II Integrin α5 AB1949 Merck Millipore, Burlington, MA IFM 
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 Antigen Catalog no. Supplier Method 
II 
Alexa Fluor® 488 
conjugated 
phalloidin 
A12379 Invitrogen, Carlsbad, CA, USA IFM 
II pSrc 2101 Cell Signaling Technology WB 
II Src 2108 Cell Signaling Technology WB 
III p53 DO-1 Santa Cruz Biotechnology WB 
III p53 DO-7 Sigma-Aldrich, St Louis, MO IHC 
III p21 2G12 BD Biosciences WB 
III pSTAT3 D3A7 Cell Signaling Technology WB, IHC 
III STAT3 124H6 Cell Signaling Technology WB 
III MMP-1 IM35L CalbioChem, La Jolla, CA WB 
III MMP-3 HPA007875 Sigma-Aldrich WB 
III MMP-10 MA5-14233 Thermo Fisher Scientific WB 
III MMP-13 IM64L CalbioChem WB 
III TIMP-1 IM32 CalbioChem WB 
III CD34 sc-18917 Santa Cruz Biotechnology IHC 
I-III β-actin A-1978 Sigma-Aldrich WB 
4.4 Quantitative real-time PCR 
Total RNA was extracted from the cultured cSCC cells and tissue samples using 
RNeasy mini kit (Qiagen) and cDNA was synthetized. RealTimeDesign Software 
(https://www.biosearchtech.com) was used to design specific primers and probes 
(Oligomer, Helsinki, Finland). All the primers and probes used in the original 
publications (I-III) are listed in Table 3. All qRT-PCR reactions were performed in 
triplicate using the ABI 7900 (Applied Biosystems, Carlsbad, CA) or QuantStudio 
12K Flex (Thermo Fisher Scientific) system at the Finnish Functional Genomics 
Centre (FFGC) in Turku, Finland. The standard curve method was used to analyze 
the results (Larionov et al, 2005). 
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Table 3. Primers and probes used in the original publications in qRT-PCR. 
 Primer or probe Sequence 
I, II  PICSAR forw 5′-TGC CTG GAC TTT CAA GAG GTA A-3′ 
 PICSAR rev 5′-GCT CTC AGT CAG CAG ACA CTT-3′ 
 PICSAR probe 5′-Fam CCG AGC TCT GCT CTG AGG CCT BHQ1-3′ 
I DUSP6 forw 5′-GCC GCA GGA GCT ATA CGA G-3′ 
 DUSP6 rev 5′-ACC GGC AGG TTA CCC TTC T-3′ 
 DUSP6 probe 5′-Fam TCG TCG CAC ATC GAG TCG GC BHQ1-3′ 
II Integrin α2 forw 5′‐TGG ATT TGC GTG TGG ACA TC‐3′ 
 Integrin α2 rev 5′‐GGC AGT TCT AGA ATA GGC TTC AA‐3′ 
 Integrin α2 probe 5′‐Fam-TCT GGA AAA CCC TGG CAC TAG CCC TG-BHQ1‐3′ 
II Integrin α5 forw 5′-GGG TGG CCT TCG GTT TAC AG-3′ 
 Integrin α5 rev 5′-GCT TTG CGA GTT GTT GAG ATT C-3′ 
 Integrin α5 probe 5′-Fam TCC CTC ATC TCC GGG ACA CTA A BHQ1-3′ 
II Integrin β1 forw 5′-CAA GGG CAA ACG TGT GAG A-3′ 
 Integrin β1 rev 5′-TGA AGG CTC TGC ACT GAA CA-3′ 
 Integrin β1 probe 5′-Fam TGT GTC AGA CCT GCC TTG GTG TC BHQ1-3′ 
III MALAT1 Proprietary (cat. Hs00273907_s1, Thermo Fischer Scientific) 
III MMP-1 forw 5′-AAG ATG AAA CGT GGA CCA ACA ATT-3′ 
 MMP-1 rev 5′-CCA AGA GAA TGG AAG AGT TC-3′ 
 MMP-1 probe 5′-Fam CAG AGA GTA CAA CTT ACA TCG TGT TGC GGC TC Tamra-3′ 
III MMP-3 Proprietary (cat. Hs00968305_m1, Thermo Fischer Scientific) 
III MMP-10 forw 5′-GGA CCT GGG CTT TAT GGA GAT AT-3′ 
 MMP-10 rev 5′-CCC AGG GAG TGG CCA AGT-3′ 
 MMP-10 probe 5′-Fam CAT CAG GCA CCA ATT TAT TCC TCG TTG CT Tamra-3′ 
III MMP-13 forw 5′-AAA TTA TGG AGG AGA TGC CCA TT-3′ 
 MMP-13 rev 5′-TCC TTG GAG TGG TCA AGA CCT AA-3′ 
 MMP-13 probe 5′-Fam CTA CAA CTT GTT TCT TGT TGC TGC GCA TGA Tamra-3′ 
I-III β-actin forw 5′-TCA CCC ACA CTG TGC CCA TCT ACG C-3′ 
 β-actin rev 5′-CAG CGG AAC CGC TCA TTG CCA ATG G-3′ 
 β-actin probe 5′-Fam CAG CGG AAC CGC TCA TTG CCA ATG G BHQ1-3′ 
I, II GAPDH forw 5′-ACC CAC TCC TCC ACC TTT GA-3′ 
 GAPDH rev 5′-TTG CTG TAG CCA AAT TCG TTG-3′ 
 GAPDH probe 5′-Fam ACG ACC ACT TTG TCA AGC TCA TTT CCT GGT BHQ1-3′ 
4.5 RNA sequencing and bioinformatic analyses 
RNA isolation for all RNA-seq analyses was done using the miRNeasy Mini Kit 
(Qiagen). The SOLiDTM Whole Transcriptome Analysis Kit (Applied Biosystems) 
was used to prepare the whole transcriptome libraries for cSCC cells (n = 8) and 
NHEKs (n = 4). The gene expression analysis was performed using the SOLiD 3Plus 
system at the FFGC. The reads were aligned against the human reference genome 
hg19. The quantile-to-quantile adjustment (R/Bioconductor package edgeR) was 
used in data normalization. LncRNA genes were identified based on annotated 
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lncRNAs by the HGNC (http://www.genenames.org). RNA-seq data of cSCC cell 
lines and NHEKs (GSE66412) is available online. 
The RNA-seq analyses for cSCC cells (UT-SCC12A, UT-SCC59A and UT-SCC118) 
after PICSAR knockdown and for cSCC cells (UT-SCC7, UT-SCC59A, UT-SCC105) 
after PRECSIT knockdown were performed using the Illumina HiSeq2500 system 
(Illumina, San Diego, CA) at the FFGC. The reads were aligned against the human 
reference genome hg19 for PICSAR knockdown RNA-seq and hg38 for PRECSIT 
knockdown RNA-seq. TMM normalization method was used for data normalization 
(R/Bioconductor package edgeR). Morpheus software was used to generate heatmaps 
(https://software.broadinstitute.org/morpheus). RNA-seq data was analyzed using 
Ingenuity Pathway Analysis (Ingenuity Systems, Redwood City, CA; FC log2 > 0.5, P < 
0.05), the Gene Ontology Enrichment Analysis (http://www.geneontology.org/), Kyoto 
Encyclopedia of Genes and Genomes Pathway Analysis (http://www.genome.jp/kegg/) 
and the Reactome Pathway Knowledgebase (https://reactome.org/). RNA-seq data of 
PICSAR knockdown cSCC cells (GSE77950) is available online.  
Following computational programs were used to evaluate potential miRNA 
binding sites in PICSAR; TargetScan (http://www.targetscan.org) (Agarwal et al, 
2015), miRWalk (http://mirwalk.umm.uni-heidelberg.de/) (Dweep and Gretz, 2015) 
and DIANA–lncBase v2 (www.microrna.gr/LncBase) (Paraskevopoulou et al, 2015). 
4.6 Western blot analysis 
Samples of cSCC cultures were analyzed by western blotting with antibodies listed in 
Table 2. Protein expression was quantitated using the LI-COR Odyssey® CLx 
fluorescent imaging system with fluorescently-labeled secondary antibodies (LI-
COR Biosciences, Lincoln, NE). 
4.7 Flow cytometry (II) 
To quantitate integrin expression on the cell surface cell cultures were trypsinized 
and 700 000 cells per sample was suspended in 1 % FCS-PBS and incubated on ice 
for 30 minutes. Cells were stained with monoclonal antibodies listed in Table 2 for 
1 hour in +4°C in agitation and washed with PBS. Alexa Fluor® 488 conjugated goat 
anti-mouse antibody was used as a secondary antibody (Table 2). FACSCalibur flow 
cytometer (BD Biosciences) was used for cell analysis at the FFGC. Flowing Software 
2.5.1 (Turku Centre for Biotechnology, University of Turku, Finland, 
www.flowingsoftware.com) was used for data analysis. 
To analyze cell cycle cSCC cultures were trypsinized 72 hours after siRNA 
transfection, followed by washing with PBS and suspension in sodium citrate buffer 
(40 mM Na-Citrate, 0.3% Triton X-100, 0.05 mg/ml propidium iodide, PBS). After 
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20 minutes of incubation cell cycle analysis was performed using BD LSR 
FortessaTM cell analyzer (BD Biosciences) at the Cell Imaging Core of the Turku 
Centre for Biotechnology, Turku, Finland. The FlowJo software, v.10 (Tree Star Inc., 
Ashland, OR) was used to analyze the results. 
4.8 Protein and RNA detection in fixed cells and 
tissues 
4.8.1 Immunofluorescence (II) 
Cell cultures were fixed with 4% paraformaldehyde-PBS for 10 minutes, blocked with 
3 % BSA-PBS for 30 minutes and permeabilized with 0.2 % Triton X-100-PBS for 5 
minutes. Cells were labeled with primary antibodies listed in Table 2 in 3 % BSA-
PBS for 3 hours. Alexa Fluor® 568 conjugated goat anti-mouse or anti-rabbit 
antibody (Invitrogen) was used as secondary antibody in 1:200 dilution together with 
Alexa Fluor® 488 conjugated phalloidin in 1:50 dilution in 3 % BSA-PBS. Hoechst 
33342 (Thermo Fisher Scientific) was used to visualize nuclei. Cells were mounted 
with Mowiol-DABCO (Sigma-Aldrich) and samples were examined with Zeiss 
AxioVert 200M (Carl Zeiss, Jena, Germany). 
4.8.2 RNA in situ hybridization (I, III) 
Formalin-fixed paraffin-embedded tissue samples were subjected for RNA in situ 
hybridization (RNA-ISH) analysis using QuantiGene® ViewRNATM ISH Tissue 
Assay kit (Affymetrix, Inc., Santa Clara, USA) with TYPE 1 probe set for PICSAR 
and TYPE 6 probe set for MMP13 (both from Affymetrix) according to the 
manufacturer’s instructions. Fast Red and Fast Blue substrates (Affymetrix) were 
used to detect alkaline phosphatase activity in TYPE 1 probe set for PICSAR and 
TYPE 6 probe set for MMP13, respectively. Tissue sections were visualized using a 
brightfield microscope Olympus BX60 (Olympus Optical Co., Ltd., Tokyo, Japan). 
For the negative control hybridization the probe sets were omitted. 
For PRECSIT detection in situ formalin-fixed paraffin-embedded tissue samples 
were subjected for RNA-ISH analysis using RNAscope® ISH Assay (Advanced Cell 
Diagnostics, Newark, CA) in cooperation with Bioneer (Bioneer A/S, Hørsholm, 
Denmark, http://www.bioneer.dk). The assay was performed by using automated 
Ventana Discovery Ultra slide-staining system (Roche, Basel, Switzerland) as 
previously described (Anderson et al, 2016). PRECSIT-specific probe (cat. 559389) 
was designed and purchased at Advanced Cell Diagnostics (ACD, Newark, CA). 
Human PPIB (Cyclophilin B) and bacterial DapB (4-hydroxy-tetrahydrodipicolinate 
reductase) mRNAs were used as positive and negative controls for RNA-ISH (III, 
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Supplementary Figure S3). PRECSIT expression was visualized using the 
Pannoramic Midi FL slide scanner (3DHISTECH Ltd., Budapest, Hungary) and 
quantitated by counting PRECSIT positive cells and compared with the number of 
total cell count in a section at 40x magnification using QuPath bioimage analysis 
software (Bankhead et al, 2017). 
RNA-ISH analysis of cultured cSCC cells and NHEKs was performed with 
QuantiGene® ViewRNATM ISH Cell Assay kit according to the manufacturer’s 
instructions (Affymetrix). Cells were fixed in 4% paraformaldehyde for 30 minutes 
treated with protease (1:2 000) and hybridized with PICSAR specific probe set. For 
nuclear staining 4,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) or Hoechst 
(Thermo Fisher Scientific) was used. Fluorescence signal of PICSAR was detected 
using Zeiss LSM 510 META or Zeiss AxioVert 200M microscopes. 
4.8.3 Immunohistochemistry (I, III) 
To evaluate tumor histology tissue samples from paraffin-embedded formalin-fixed 
human cSCC xenograft tumors were stained with Mayer’s hematoxylin (Sigma-
Aldrich) and or eosin (Junttila et al, 2007). Proliferating cells were identified by 
immunohistochemistry using monoclonal antibody for Ki-67 (Table 2) with 
hematoxylin as counterstain. The relative number of Ki-67-positive cells was 
determined by counting 500-2 600 cells at 20x magnification in all tumor sections 
with ImageJ Software (Schneider et al, 2012).  
Tissue microarrays from NS, SK, AK, cSCCIS and invasive cSCC were stained with 
mouse monoclonal p53 antibody (Table 2) at the Histology Core of the Institute of 
Biomedicine at the University of Turku and visualized using the Pannoramic Midi FL 
slide scanner (3DHISTECH Ltd.). This antibody reacts with the mutant and the wild-
type p53. A semiquantitative analysis was performed to evaluate the p53 expression 
and mutational status based on the staining intensity of p53; - negative (no expression, 
likely a missense mutation in p53 resulting in no protein expression), + weak (very 
weak expression in the basal layer of the skin, presumably functional wild-type p53), 
++ moderate (moderate nuclear p53 expression throughout the epidermis, p53 may be 
functional and activated), +++ strong (strong nuclear accumulation of p53 in the 
majority of cells, p53 is likely mutated and non-functional).  
4.9 Construction of expression vectors (II) 
Primer-BLAST was used for designing specific primers for PICSAR (Oligomer): 
forward primer 5’-CTGGCTCACCCTGGCACTG-3’, reverse primer 5’-
CACCTAAGCAATGCAGAGAGG-3’. Q5® High-Fidelity DNA Polymerase (New 
England Biolabs, Ipswich, MA) was used to amplify the DNA by PCR using cSCC 
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cell derived cDNA as template. The PCR reaction was cycled as follows; 98°C 30s; 
98°C 10s, 66°C 30s and 72°C 30s (40 cycles); 72°C 10 minutes. The DNA fragment 
was cloned into pcDNA3.1(-) (Invitrogen) containing the neomycin resistance gene. 
The construct was further sequenced to verify the orientation and integrity of the 
ligated PICSAR insert. 
4.10 Functional assays in cell culture 
4.10.1 Cell transfections (I, II, III) 
4.10.1.1 Gene knockdown using small interfering RNAs 
Cells were cultured to 50 % confluence and transfected with commercially available 
small interfering RNAs (siRNAs) (Table 4) at 75 nM concentration (Qiagen) in 
serum-free medium using siLentFectTM Lipid Reagent (Bio-Rad). After 6 h, the 
medium was equilibrated to 10% FCS. To obtain p38α/δ double knockdown, both 
siRNAs were added in a final concentration of 75 nM and control cells were 
transfected using control siRNA in final concentration of 150 nM. 
4.10.1.2 Cell transfection with a gene expression construct (II) 
Lipofectamine 3000 transfection reagent (Invitrogen) was used to transfect cSCC 
cells with an empty vector (pcDNA3.1) or PICSAR expression construct 
(pcDNA3.1_PICSAR) and transfected cells were selected with 1 µg/ml Geneticin 
(G418 sulfate, Invitrogen). Selective pressure of PICSAR expression in cSCC cells 
was maintained using 500 µg/ml Geneticin. 
Table 4. Commercially available siRNAs used in the original publications. 
 Target gene Catalog no. Sequence 
I-III  AllStars Negative Control siRNA SI03650318 proprietary 
I, II PICSAR  SI04916219 (PICSAR siRNA1) 5′-CACGGCCAACGTGGAGCTCTA-3′ 
I, II PICSAR SI04916233        (PICSAR siRNA2) 5′-CTGCAGTCACTTCACAGTGAA-3′ 
I p38α SI00605157 5′-CAGAGAACTGCGGTTACTTAA-3′ 
I p38δ SI02222941 5′-CCGGAGTGGCATGAAGCTGTA-3′ 
III PRECSIT SI04765145     (PRECSIT siRNA1)  5′-GAGGTTCGGGAAGGAAAGGAAA-3′ 
III PRECSIT SI04765159     (PRECSIT siRNA2) 5′-CAGGGATGGTGACAAGCGGAA-3′ 
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4.10.2 Inhibitor assays (I, III) 
For a specific inhibition of MAPKs, cSCC cells were treated with p38 inhibitors 
BIRB796 and SB203580 (10 μM), and MEK1/2 inhibitor PD98059 (30 μM) (all from 
Calbiochem) for 24 hours. For DUSP6 inhibition cSCC cells were treated with (E)-
2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one (BCI) (5 μM, 
Calbiochem) for 6 hours and incubation was continued for 18 hours with 1 μM BCI. 
For STAT3 inhibition cSCC cells were treated with 100 µM STAT3 inhibitor S31-
201 (Cayman Chemical, Ann Arbor, MI). 
4.10.3 Adenoviral infection (I, III) 
UT-SCC12A cells were infected with control (RAdLacZ) and dominant negative 
MKK3bcontaining (RAdMKK3bA) adenoviral vectors and incubated for 6 hours in 
0.5 % FCS at MOI 600. UT-SCC7, UT-SCC12A and HaCaT cells were infected with 
RAdp53 containing the p53 wild-type (Katayose et al, 1995) or with empty virus 
RAd66 (Wilkinson and Akrigg, 1992) and incubated as previously. Recombinant 
adenovirus for dominant negative MKK3b (RAdMKK3bA) (Wang et al, 1998) was 
kindly provided by Dr. Jiahuai Han (Scripps Research Institute, La Jolla, CA, USA). 
Escherichia coli β-galactosidase containing recombinant adenovirus (RAdLacZ) 
(Wilkinson and Akrigg, 1992) was kindly provided by Dr. Gavin W.G. Wilkinson 
(University of Cardiff). 
4.10.4 Analysis of cell viability and proliferation (I) 
Viability of PICSAR and control siRNA treated cSCC cells was determined using 
WST-1 cell proliferation reagent (Roche). After 48 and 72 hours of siRNA 
transfection cells were seeded in a 96-well plate and absorbance was measured in 450 
nm (Multiskan FC microplate reader, Thermo Fisher Scientific) after 1 hour of 
incubation with the WST-1 reagent in +37°C.  
4.10.5 Cell adhesion assays (II) 
To study real-time cell adhesion cSCC cells were seeded on collagen I (PureCol, 
Advanced BioMatrix, Carlsbad, CA) or fibronectin (Merck Millipore, both 5 µg/cm2) 
coated electronic microtiter plate (E-Plate 96, Roche) and cell adhesion was 
measured using the xCELLigence real-time cell analyzer (RTCA; Roche).  
The formation of lamellipodia was studied by microscopic quantitation of cSCC 
cells. Cells were plated on collagen I or fibronectin coated 96-wells (both 5 µg/cm2) 
and fixed 4 hours after plating (8% formaldehyde, 10% sucrose in PBS supplemented 
with 1 mM MgSO4 and 1 mM CaCl2) for 30 minutes in room temperature. The 
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number of cells with lamellipodia or spread cells was compared to the total cell 
number in each well from three parallel wells (three images per well) at 20x 
magnification. 
4.10.6 Cell migration assays (I, II) 
Cell migration was studied in wound healing assay either manually or using the the 
IncuCyte ZOOM® real-time cell imaging system. Cultures of cSCC cells were grown 
to confluency and hydroxyurea was added in 1 mM final concentration in DMEM 
with 10 % FCS to prevent proliferation of cells. After 6 hours cell monolayer was 
scratched and incubation was continued in 1% FCS with 0.5 mM hydroxyurea. Cells 
were imaged either using the Olympus IX70 inverted microscope (Olympus Optical 
Co.) or the IncuCyte ZOOM®. The data analysis was done either manually by 
measuring the mean area of the cell deprived scratch zone and comparing it to the 
0h time point using ImageJ software (Schneider et al, 2012) or using the IncuCyte 
ZOOM 2014A software. 
To study the migration of individual cSCC cells they were plated on ImageLock™ 
96-wells coated with fibronectin or collagen I (both 5 µg/cm2) and imaged every 10 
minutes using the IncuCyte ZOOM® real-time cell imaging system. Individual 
migrating cells were tracked using the ImageJ software. 
4.10.7 Cell invasion assay (III) 
To study cell invasion cSCC cells were plated on collagen type I coated (5 µg/cm²; 
PureCol, Advanced BioMatrix) ImageLock 96-well plate (Essen Bioscience) 24 hours 
after transfection with PRECSIT siRNAs or negative control siRNA and cells were 
let to adhere overnight. Cell monolayer was scratched and cells were overlaid with 
collagen type I solution by mixing type I collagen (PureCol) with 5X Dulbecco's 
Modified Eagle Medium (DMEM) and 0.2 M HEPES buffer (pH 7.4) at a ratio of 
7:2:1, respectively. Finally, 1 M NaOH was added to obtain the final pH at 7.4. The 
collagen I solution (2.2 mg/ml) was let to polymerize for 2 hours at +37°C and cell 
culture medium with 0.5 % fetal calf serum was added on top. The gap closure was 
imaged and the relative cell invasion was quantitated using the IncuCyte ZOOM® 
2016B software. 
4.11 Human cSCC xenograft model (I, III) 
For human cSCC xenograft model UT-SCC12A cells were transfected with PICSAR 
or control siRNA. UT-SCC7 cells were transfected with PRECSIT or control siRNA. 
Cells were detached 72 hours after transfection and injected subcutaneously in 100 
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μl of phosphate buffered saline (7×106 UT-SCC12A cells and 5×106 UT-SCC7 cells) 
into the back of 6 weeks old female SCID mice (CB17/Icr-Prkdcscid/IcrIcoCrl) 
(Charles River Laboratories, Wilmington, MA) (n = 7 for control and PICSAR 
knockdown tumors; n = 6 for control and n = 8 for PRECSIT knockdown tumors). 
Tumor size was measured twice a week and the volume of tumors was calculated as 
V = (length × width2)/2 (Euhus et al, 1986). Mice were sacrificed 18 or 16 days after 
tumor implantation and tumors were excised, weighed and fixed in fresh phosphate-
buffered 4 % paraformaldehyde for 24 hours at +4°C. Fixed tumors were embedded 
in paraffin and sectioned for 5-μm-thick slices for immunostaining (Junttila et al, 
2007). 
4.12 Statistical analysis 
The SPSS Statistics software, v. 20.0 and v. 25 (IBM, Armonk, NY) was used for 
statistical analyses. Two-tailed Student’s t-test and two-tailed Mann-Whitney U-test 
were used for group comparisons. Fisher’s exact test was used for statistical analysis 
with immunohistochemistry stainings. 
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5 Results 
5.1 Expression of several lncRNAs is altered in 
cSCC cells compared to NHEKs (I, III) 
A whole-genome-wide expression profiling was performed for cSCC cell lines 
(primary n=5, metastatic n=3) and NHEKs (n=4) using the SOLiD 3Plus system. The 
analysis revealed several differentially regulated lncRNA genes in cSCC cells 
compared to NHEKs (I, Figure 1a) (Figure 6). Among these, LINC00162 (PICSAR) 
was the most upregulated lncRNA in cSCC cells compared to NHEKs. As the second 
most upregulated lncRNA was LINC00346 (PRECSIT). These two lncRNAs were 
selected for further investigation.  
 
Figure 6. Expression profile of lncRNAs in cSCC cells and NHEKs. A heatmap showing 
significantly (P<0.05) regulated lncRNAs in cSCC cell lines compared to NHEKs. The Mann-
Whitney U-test was used for statistical analysis. 
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5.2 LncRNAs PICSAR and PRECSIT are specifically 
upregulated in cSCC (I, III) 
Analysis with qRT-PCR verified 
overexpression of PICSAR and 
PRECSIT in cSCC cell lines 
(n=6–8) compared to NHEKs 
(n=7–8) (I, Figure 1b; III, Figure 
1a). PRECSIT localization was 
noted mostly in the nuclear cell 
fraction (III, Figure 1b), 
whereas PICSAR was enriched 
in the cytoplasmic cell fraction 
by qRT-PCR analysis (Figure 
7). PICSAR was upregulated 
also in cSCC tissues in vivo by 
qRT-PRC analysis (n=6), 
whereas its expression in 
normal skin (n=7) was very low 
(I, Figure 1c).  
Mainly cytoplasmic signal was noted for PICSAR in cSCC cells using RNA in situ 
hybridization (RNA-ISH) but no PICSAR expression was noted in NHEKs in culture 
(I, Figure 1d, Supplementary Figure S2). Specific expression of PICSAR was noted 
also in tumor cells in tissue sections of xenografts established with human cSCC cells 
(UT-SCC12A) (I, Figure 1e). MMP-13 mRNA expression was detected in cSCC cells 
in the same xenografts as a positive control (I, Figure 1e) (Airola et al, 1997, Stokes 
et al, 2010). PRECSIT expression in situ was noted in xenografts established with 
human cSCC cells (UT-SCC7) showing the highest expression level at the edge of the 
tumors whereas in the inner tumor mass the expression of PRECSIT was relatively 
low (III, Figure 4e). Localization of PRECSIT was noted in the cytoplasm and nucleus 
of the tumor cells, with a prevalent appearance in the perinuclear region (III, Figure 
4e). 
To investigate PICSAR and PRECSIT expression in vivo in NS, SK, AK, cSCCIS 
and invasive cSCC formalin-fixed paraffin-embedded tissue samples were subjected 
to RNA-ISH analysis. Specific PICSAR expression was noted in tumor cells in AK 
(n=26), cSCCIS (n=20), and cSCC (n=21), whereas no signal was detected in normal 
skin (n=9) (I, Figure 2a–d). The number of PICSAR positive tissue sections was the 
highest in invasive cSCC (43 %), whereas all NS sections were negative for PICSAR 
(I, Figure 2e). The number of PICSAR positive sections was also higher in cSCCIS 
(35 %) when compared to AK (23 %) (I, Figure 2e). Primarily nuclear localization 
was noted for PRECSIT in vivo (III, Figure 1c-g). The percentage of PRECSIT 
Figure 7. PICSAR is preferentially expressed in the 
cytoplasm of cSCC cells. qRT-PCR analysis of 
PICSAR expression in the nuclear and cytoplasmic cSCC 
cell fractions. β-Actin and MALAT1 were used as controls 
for cytoplasmic and nuclear RNA expression. Mean±SD 
is shown (n=3). 
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positive cells was significantly higher in invasive cSCC when compared with NS, SK, 
AK and cSCCIS (III, Figure 1h). PRECSIT expression was also higher in AK and 
cSCCIS when compared with SK (III, Figure 1h). Nearly half (49 %) of the invasive 
cSCCs showed strong PRECSIT expression (>30 % PRECSIT positive cells) whereas 
mostly weak (<15 % PRECSIT positive cells) or moderate (15-30 % PRECSIT 
positive cells) PRECSIT expression was noted in NS and SK (III, Figure 1i). PRECSIT 
copy number was quantified by counting the number of PRECSIT particles per cell. 
There was significantly higher percentage of cells expressing high level of PRECSIT 
(≥5 particles per cell) in invasive cSCC (III, Figure 1d) when compared to NS, SK, 
AK or cSCCIS (III, Figure 1j). In addition, the relative number of tumor cells 
detected with ≥5 PRECSIT particles correlated with the overall percentage of 
PRECSIT positive cells in tissue sections of SK, AK, cSCCIS and invasive cSCC (III, 
Supplementary Figure S2).  
5.3 Regulation of lncRNAs in cSCC (I, III) 
5.3.1 Regulation of PICSAR expression by the p38 MAPK 
pathway (I) 
The regulation of PICSAR basal expression was investigated by specifically inhibiting 
p38 and ERK1/2 MAPKs in cSCC cells. By inhibiting all p38 isoforms (p38α/β/δ) by 
BIRB796 PICSAR expression was significantly upregulated (I, Figure 3a). Treatment 
with SB203580, inhibiting p38α and p38β isoforms, or with PD98059 inhibiting 
MEK1/2 upstream of ERK1/2 had no effect on the expression of PICSAR (I, Figure 
3a). Next, expression of p38α and p38δ was inhibited in cSCC cell by siRNA-
mediated knockdown or by delivering a dominant negative mutant of MAP kinase 
kinase 3b (RAdMKK3bA), an upstream activator of p38α and p38δ, into cSCC cells. 
Inhibition of p38α and p38δ expression in cSCC cells resulted in a significant 
upregulation of PICSAR (I, Figure 3b and c), in consistent with the findings with the 
p38 inhibitor assay. 
5.3.2 Regulation of PRECSIT expression by the p53 pathway 
(III) 
Most of the cSCC cells used in this study harbor mutations in TP53 gene resulting in 
a nonfunctional p53 protein (III, Supplementary Table S1).  The expression of p53 
in vivo was examined by IHC analysis  using an antibody that recognizes both the 
wild-type and mutated p53 and based on the p53 staining intensity the tissues were 
categorized in four groups; weak (+), moderate (++), strong (+++) and negative (-) 
(III, Figure 2a, Supplementary Table S1). Strong p53 staining or absence of p53 was 
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detected only in malignant tissues, cSCC, cSCCIS, and AK, indicating mutationally 
inactivated p53 in these tissues (III, Figure 2a and b). All NS lesions showed weak 
nuclear p53 staining in the basal epidermal keratinocytes (III, Figure 2a and b).  
The p53 expression level was compared with PRECSIT expression in parallel 
tissue sections in vivo. High level of PRECSIT expression (>30 % PRECSIT positive 
cells) was noted in AK, cSCCIS and cSCC tissues within all p53 staining groups 
(weak, moderate, strong and negative), but there was no correlation between the 
relative number of PRECSIT positive cells and p53 intensity (III, Figure 2c). 
However, 56% of all cSCC tissue sections showed PRECSIT accumulation (≥5 
PRECSIT particles per cell) and the majority of these tissue sections (45%) showed 
negative p53 immunoreactivity (III, Figure 2d and e, Supplementary Table S3). 
Interestingly, this represents 84% of all p53 negative cSCC tissue samples, indicating 
that accumulation of PRECSIT correlates with the absence of p53 expression in 
cSCC. PRECSIT accumulation was correlated with negative p53 immunoreactivity 
also in AK and cSCCIS, where PRECSIT accumulation was noted in 75 % of all p53 
negative lesions (III, Figure 2e, Supplementary Table S3). In addition, the fraction of 
lesions with strong p53 staining intensity detected with PRECSIT accumulation was 
higher in cSCC tissues (41 %) when compared with AK and cSCCIS (10 %) (III, 
Figure 2e, Supplementary Table S3). In contrast, minority of the AK, cSCCIS (10 %) 
and cSCC tissue sections (10 %) detected with PRECSIT accumulation correlated 
with weak (+) p53 staining, as an indicative of a functional p53 in vivo (III, Figure 
2e, Supplementary Table S3). 
To support these observations, the qRT-PCR analysis of the p53 mutation 
bearing HaCaT cell line (Boukamp et al, 1988) showed significantly higher PRECSIT 
expression compared to NHEKs (III, Figure 2f). Furthermore, adenoviral delivery of 
a wild-type p53 into HaCaT or cSCC cells resulted in downregulation of PRECSIT 
expression, showing that the expression of PRECSIT is regulated by p53 (III, Figure 
2g and h). 
5.4 Molecular functions of lncRNAs in cSCC (I, II, III) 
5.4.1 Regulation of cSCC cell migration and adhesion by 
PICSAR (I, II) 
5.4.1.1 Alteration of the gene expression profile of cSCC cells after 
PICSAR knockdown (I, II) 
To investigate the molecular mechanisms of PICSAR, RNA-seq was performed with 
PICSAR knockdown cSCC cells (UT-SCC12A, UT-SCC59A, and UT-SCC118) (I, 
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Figure 4a). Differentially expressed genes (DEG) after PICSAR knockdown were 
significantly associated with specific biofunctions M-phase of tumor cell lines, 
transformation of tumor cell lines, and phosphorylation of L-serine by the ingenuity 
pathway analysis (I, Figure 5a, upper panel). In addition, ERK/MAPK signaling was 
significantly associated (P<0.0001) with DEGs in PICSAR knockdown cSCC cells (I, 
Supplementary Figure S5). 
The analysis of DEGs after PICSAR knockdown revealed  significantly enriched 
GO terms such as cell proliferation (P=5.5×10–7), response to wounding (P=4.0×10–6), 
and regulation of cell migration (P=1.4×10–5) (I, Figure 5a, lower panel). GO terms 
laminin binding (P=4.1×10–4), extracellular matrix binding (P=9.0×10–4), and 
peptidase regulator activity (P=1.1×10–3) were also associated with DEGs after 
PICSAR knockdown in cSCC cells (I, Figure 5a, lower panel). Significantly enriched 
KEGG pathways associated with DEGs after PICSAR knockdown included 
complement and coagulation cascades (P=6.6×10–3), hematopoietic cell lineage 
(P=2.3×10–2), and extracellular matrix-receptor interaction (P=2.4×10–2) (I, Figure 
5a, lower panel). The 50 most up- and downregulated genes (P<0.05, FC log2>0.7) 
after PICSAR knockdown are shown in Figure 5b (I). The full list of the top regulated 
genes in PICSAR knockdown cSCC cells is included in the Supplementary Tables S1 
and S2 (I). 
5.4.1.2 PICSAR regulates cSCC cell migration on collagen I and 
fibronectin (I, II) 
To study the cellular functions of PICSAR cSCC cells were transfected with two 
PICSAR targeted siRNAs and control siRNA and harvested 72 hours after 
transfection. Effective PICSAR knockdown in cSCC cells was detected using RNA-
ISH (I, Figure 4a, lower panel; Supplementary Figure S3) and qRT-PCR analysis (I, 
Figure 4a, upper panel; Supplementary Figure S4a). Analysis of cell migration after 
PICSAR knockdown was performed with two cSCC cell lines (UT-SCC12A and UT-
SCC118). The wound healing assay showed that knockdown of PICSAR decreased 
cell migration significantly in comparison with the control siRNA transfected cells 
(I, Figure 4d and e, Supplementary Figures S4d and S4e). 
To examine cell motility in more detail real-time cell migration assay was 
performed to track individual cell migration on fibronectin and collagen I. Decreased 
cell migration was noted in cSCC cells (UT-SCC12A and UT-SCC59A) after 
PICSAR knockdown on fibronectin and collagen I (II, Figure 1a; Supplementary 
Figure S1a). 
Stably PICSAR overexpressing cSCC cells were generated by transfecting UT-
SCC59A with PICSAR expression construct (pcDNA3.1_PICSAR) or empty vector 
(pcDNA3.1) and transfected cells were selected with Geneticin. PICSAR expression 
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level was confirmed by qRT-PCR of the transfected UT-SCC59A cells (II, Figure 3a). 
Migration of PICSAR overexpressing cSCC cells was studied in a wound healing 
assay. PICSAR overexpression increased migration of cSCC cells compared to 
control cells (II, Figure 3f). 
5.4.1.3 PICSAR regulates cSCC cell adhesion and spreading on 
collagen I and fibronectin (II) 
To quantitate real-time cell adhesion of cSCC cells after PICSAR knockdown cSCC 
cells (UT-SCC12A and UT-SCC59A) were transfected with PICSAR siRNA or 
control siRNA and plated on fibronectin or collagen I and cell adhesion was 
measured using the xCELLigence system. PICSAR knockdown significantly 
increased cSCC cell adhesion on collagen I and fibronectin compared to the control 
siRNA transfected cells (II, Figure 1b; Supplementary Figures S1b and S2a). In 
addition to dynamic monitoring of cell adhesion cells were fixed to quantitate cell 
spreading on fibronectin and collagen I. cSCC cells (UT-SCC12A and UT-SCC59A) 
were transfected with PICSAR siRNA or control siRNA and plated on fibronectin or 
collagen I. The morphology of PICSAR knockdown cSCC cells was less spherical 
compared to the control cells and the number of cells with lamellipodia was 
significantly higher in PICSAR knockdown cSCC cells (UT-SCC12A and UT-
SCC59A) compared to the control siRNA transfected cells on fibronectin and 
collagen I (II, Figure 1c, Supplementary Figures S1c and S2b). 
Adhesion of stably PICSAR overexpressing cSCC cells was significantly 
decreased on fibronectin and collagen I compared to the control cells (II, Figure 3e). 
Furthermore, PICSAR overexpression resulted in impaired cell spreading (II, Figure 
3c). The relative number of spread cells was significantly decreased in PICSAR 
overexpressing cells compared to the control cells (II, Figure 3c). 
5.4.1.4 PICSAR regulates integrin and Src expression in cSCC cells (I, 
II) 
The bioinformatic analysis of the cSCC cell gene expression profile after PICSAR 
knockdown revealed several differentially expressed genes associated with specific 
biological processes, such as extracellular matrix binding and extracellular matrix-
receptor interaction (I, Figure 5a), suggesting that PICSAR is regulating genes 
involved with cell adhesion. To study this in detail, DEGs specifically functioning in 
cell adhesion (Winograd-Katz et al., 2014) were examined in the PICSAR 
knockdown RNA-seq (II, Figure 2a). Several of them were significantly regulated, 
including genes coding for proto-oncogene SRC and integrins, particularly ITGA2, 
ITGA5 and ITGB1 encoding the α2, α5 and β1 integrin subunits. 
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Elevated levels of α2, α5 and β1 integrin mRNAs were noted in cSCC cells after 
PICSAR knockdown (II, Figure 2b; Supplementary Figure S3a). Furthermore, 
increased expression of α2, α5 and β1 integrins on the surface of cSCC cells was noted 
after PICSAR knockdown by flow cytometry analysis compared to the control siRNA 
transfected cells (II, Figure 2c; Supplementary Figure S3b). Immunofluorescence 
staining for α2 and α5 integrins showed similar localization to the cell surface and 
adhesion sites both in control siRNA and PICSAR siRNA transfected cSCC cells, 
indicating that the localization of α2 and α5 integrins is not affected by PICSAR 
knockdown (II, Figure 2d). In addition to integrin regulation, decreased Src protein 
level in cSCC cells was noted after PICSAR knockdown (II, Figure 3g; Supplementary 
Figures S4a and b).  
PICSAR overexpression in cSCC cells resulted in significant decrease in α2, α5 
and β1 integrin mRNA and protein levels on the cell surface, determined by qRT-
PCR and flow cytometry analysis (II, Figures 3a and 3b). Immunofluorescence 
staining of PICSAR overexpressing cSCC cells revealed expression of α2 and α5 
integrins on collagen I and fibronectin, however when compared to the control cells 
no distinct adhesion sites were detected likely due to decreased cell spreading (II, 
Figure 3d). In consistent with these results, a significant induction of Src expression 
was noted in PICSAR overexpressing cSCC cells (II, Figure 3g; Supplementary 
Figure S4c), suggesting a regulatory link between PICSAR, Src and integrins in 
mediating cSCC cells adhesion and spreading.   
By complementary base pairing lncRNAs can bind to miRNAs and regulate 
mRNA stability indirectly and several miRNAs have been shown to regulate integrin 
expression (Chen et al, 2013). However, no potential miRNA-binding sites were 
found for PICSAR by using bioinformatic analyses, which could explain the 
regulation of integrin expression by PICSAR. 
5.4.2 PICSAR promotes growth of cSCC cells by activating 
ERK1/2 (I) 
5.4.2.1 Knockdown of PICSAR decreases cSCC cell viability (I) 
Viability of cSCC cells was studied by determining the number of viable cells 48 and 
72 hours after PICSAR knockdown. The number of viable cSCC cells (UT-SCC12A 
and UT-SCC118) was significantly decreased after PICSAR knockdown compared 
with control cells (I, Figure 4b; Supplementary Figure S4b). In addition, a marked 
decrease of expression levels for activated ERK1/2 and the Ki-67 proliferation 
marker were noted after PICSAR knockdown by analyzing the corresponding cell 
lysates (I, Figure 4c; Supplementary Figure S4c). 
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5.4.2.2 PICSAR increases activity of ERK1/2 pathway via inhibition of 
MAPK phosphatase DUSP6 (I) 
The RNA-seq of PICSAR knockdown cSCC cells revealed DUSP1 (dual-specificity 
phosphatase 1) among the most upregulated genes (P<0.05) (I, Figure 5b; 
Supplementary Table S1). It belongs to the MAPK phosphatase family and it 
dephosphorylates p38, JNK, and ERK (reviewed in Patterson et al, 2009). In 
addition to DUSP1, DUSP6, a specific negative regulator of ERK2 (reviewed in 
Patterson et al, 2009) was also noted to be upregulated after PICSAR knockdown 
(FC log2=1.09) (I, Figure 5c). Increased levels of DUSP6 mRNA and protein was 
noted after PICSAR knockdown in cSCC cells (I, Figures 5d and e; Supplementary 
Figure S6). When cSCC cells were treated with a DUSP6-specific inhibitor, 
phosphorylation of ERK1/2 was potently blocked (I, Figure 5f). However, PICSAR 
knockdown had no effect on the expression level of activated ERK1/2 in the 
presence of DUSP6 inhibitor, indicating DUSP6 as a regulatory link between 
PICSAR and ERK1/2 (I, Figure 5f). These results indicate that PICSAR promotes 
growth of cSCC cells via activation of ERK1/2 signaling pathway by 
downregulating DUSP6 expression. 
5.4.2.3 Knockdown of PICSAR suppresses growth of cSCC xenografts 
in vivo (I) 
A cSCC xenograft model using cSCC cells (UT-SCC12A) was used to investigate the 
role of PICSAR in cSCC progression in vivo. PICSAR siRNA1 and control siRNA 
transfected cSCC cells were incubated for 72 hours and injected subcutaneously into 
the back of the SCID mice. Tumor growth was measured twice a week. PICSAR 
knockdown resulted in a significant decrease in tumor growth already at the day 4 
when compared with control tumors (I, Figure 6a). Tumors were harvested 18 days 
after implantation and weighed. The mass of PICSAR knockdown tumors was 
significantly lower compared with the control tumors (I, Figure 6b). PICSAR 
knockdown resulted in a significant reduction in the relative number of proliferating 
tumor cells in cSCC xenografts when compared with the control tumors (I, Figure 
6c and d). 
Taken together, based on these findings and with the approval of the HUGO 
Gene Nomenclature Committee we named this lncRNA (LINC00162) as p38 
inhibited cutaneous squamous cell carcinoma associated lincRNA, PICSAR.  
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5.4.3 PRECSIT promotes invasion of cSCC cells by regulating 
STAT3 and matrix metalloproteinase expression (III) 
5.4.3.1 Alteration of the gene expression profile of cSCC cells after 
PRECSIT knockdown (III) 
Expression profiling of cSCC cells (UT-SCC7, UT-SCC59A and UT-SCC105) 
transfected with PRECSIT siRNA1 and control siRNA (III, Figure 3a) was performed 
with RNA-seq. The most significant GO terms associated with differentially 
expressed genes (DEG) in PRECSIT knockdown cSCC cells were biological processes 
such as negative regulation of MAPK cascade (P=8.2×10-5) and regulation of JAK-
STAT cascade (P=9.7×10-4) (III, Figure 3b). Jak-STAT signaling (P=1.1×10-4) was also 
associated with DEGs after PRECSIT knockdown by the KEGG pathway analysis 
(III, Figure 3b). The Reactome pathway analysis revealed signaling by interleukins 
(P=2.8×10-5) and cytokine signaling in immune system (P=2.6×10-3) as the most 
significantly associated pathways with DEGs after PRECSIT knockdown (III, Figure 
3b). 
5.4.3.2 Expression of STAT3 and MMPs are decreased in cSCC cells 
after PRECSIT knockdown (III) 
One of the most frequent DEGs after PRECSIT knockdown was STAT3 (III, Figure 
3c), among the top 40 most downregulated genes (P<0.05, FC log2=-1.05) (III, 
Figure 3d). In addition, several matrix metalloproteinase genes were downregulated 
(III, Figure 3d). Decreased STAT3 protein expression was confirmed by Western 
blot analysis of PRECSIT knockdown cells (III, Figure 3e). Also, decreased mRNA 
(III, Figure 3f) and protein levels (III, Figure 3g) of MMP-1, MMP-3, MMP-10 and 
MMP-13 were confirmed in UT-SCC7 cells after PRECSIT knockdown.  
5.4.3.3 Knockdown of PRECSIT inhibits invasion of cSCC cells (III) 
MMP-1 and MMP-13 have an important role in cancer invasion (reviewed in Ala-
aho & Kähäri, 2005). In addition, STAT3 has been shown to regulate cell invasion by 
controlling expression of several MMP genes in cancer cells (Itoh et al., 2006; 
Zugowski et al, 2011; Xuan et al, 2015; Jia et al, 2017; Yuan et al, 2008). To investigate 
the cellular functions of PRECSIT, cSCC cells (UT-SCC7 and UT-SCC59A) were 
transfected with two PRECSIT targeted siRNAs and negative control siRNA and 
plated on collagen I. Cell invasion through a three-dimensional type I collagen 
matrix was followed by examining the gap closure for indicated time. Cell invasion 
was significantly reduced by PRECSIT knockdown in cSCC cells (III, Figure 4a). 
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Next, cSCC cells were treated with a specific STAT3 inhibitor S31-201, resulting in 
decreased levels of MMP-1, MMP3, MMP-10 and MMP-13 in cSCC cells (III, Figure 
4b).  In consistent with this, decreased invasion of cSCC cells was noted after 
treatment with STAT3 inhibitor (III, Figure 4c). 
5.4.3.4 Knockdown of PRECSIT decreases growth of cSCC xenografts 
in vivo (III) 
The role of PRECSIT in cSCC progression was studied in vivo using a cSCC 
xenograft model established with cSCC cells. PRECSIT knockdown resulted in a 
significant decrease in tumor growth compared with control tumors (III, Figure 4d). 
Histologic analysis did not reveal a notable difference in the tumor morphology 
between the control and PRECSIT knockdown groups (III, Figure 4d). However, the 
highest PRECSIT expression was noted at the invasive edge of the xenograft tumors, 
whereas it was expressed at a markedly lower level in the inner tumor mass (III, 
Figure 4e). In addition, active STAT3 was also localized at the invasive edge of the 
xenograft tumor (III, Figure 4e). Taken together, based on these findings and with 
the approval of the HUGO Gene Nomenclature Committee we named this lncRNA 
(LINC00346) as p53 regulated carcinoma-associated STAT3 activating long 
intergenic non-protein coding transcript, PRECSIT. 
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6 Discussion 
6.1 LncRNAs as cancer biomarkers and therapeutic 
targets 
6.1.1 The potential of lncRNA biomarkers in clinical 
diagnostics 
A cancer biomarker can be used as a diagnostic indicator of the disease and some of 
them can be also used to estimate drug response or cancer prognosis. It may be for 
instance a gene mutation, a secreted molecule found in the serum or aberrant 
expression of a certain gene detected in the tumor tissue. With the current 
technology the cancer genomics is no longer restricted to studying the regulation of 
the cancer proteome but we are very aware that a lot is happening outside of the 
protein-coding genes, in the non-coding regions of the genome. The emerging 
evidence of non-coding RNA deregulation in cancer has encouraged the scientists to 
search for novel non-coding RNA markers with the help of high-throughput RNA 
sequencing technology. Long non-coding RNAs (lncRNAs) are excellent candidates 
for biomarkers as they are generally stable in body fluids, especially when delivered 
within extracellular vesicles and exosomes (Umu et al, 2018; Yuan et al, 2016). 
Currently there is at least one diagnostic test utilizing lncRNA detection in the 
clinical use (Deras et al, 2008) and many potential lncRNA-biomarkers are under 
development. When delivered outside of the cell lncRNAs can contribute to tumor 
progression for instance by manipulating the tumor microenvironment (Sang et al, 
2018; Conigliaro et al, 2015) or inducing drug resistance (Qu et al, 2016; Lei et al, 
2018). By detecting these kinds of regulators in combination with other cancer 
biomarkers they could bring valuable information to aid cancer diagnosis and 
treatment. 
6.1.2 Therapeutic targeting of lncRNAs 
The molecular background of cSCC is extensively investigated and based on several 
independent studies the mutational landscape and the gene expression profile of 
cSCC is fairly well described (Pickering et al, 2014; South et al, 2014; Li et al, 2015; 
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Inman et al, 2018). This is essential in order to identify better predictive and 
prognostic markers for cSCC. Moreover, by therapeutically targeting a specific 
cancer driver gene the oncogenic cell signaling cascade and tumor growth could be 
effectively inhibited. The massive burden of single-nucleotide mutations in cSCC 
(Pickering et al, 2014; South et al, 2014; Martincorena et al, 2015) poses a challenge 
to the clinicians to choose the right targeted therapy as it is difficult to distinguish 
between the prominent drug targets from the passenger mutations that may have 
little or no impact at all on the tumor growth. This is a serious issue particularly for 
patients with advanced cSCCs which have a high risk for recurrence and metastasis. 
Lastly, despite finding an effective treatment there is often a problem with drug 
resistance and the possibility of a crosstalk between different signaling pathways that 
may be dependent on a certain mutational combination, such as the unfortunate 
example of induced growth of cSCC tumors when using BRAF-inhibitors (reviewed 
in Wu et al, 2017).  
The inherent genomic instability of cancer cells enables them to develop different 
ways to overcome host defense. In addition to the conventionally targeted oncogenic 
factors also RNAs have been included into the drug development. There has been a 
huge improvement in generating feasible delivery methods for RNA-based therapies, 
targeting not only cancer but other diseases as well, and while many of them are 
under development (reviewed in Kaczmarek et al, 2017) a few RNA-based medicines 
are already in clinical use (Finkel et al, 2017; Adams et al, 2018). By targeting 
lncRNAs it may be possible to specifically regulate, increase (Zucchelli et al, 2015; 
Indrieri et al, 2016) or decrease protein expression (Modarresi et al, 2012; Gong & 
Maquat, 2011) without the undesirable side-effects of conventional cancer drugs. 
This is particularly interesting with certain undruggable proteins which are 
challenging for designing small-molecule inhibitors. LncRNA targeting allows very 
tissue- and cell-specific treatment. Encouraging results have been gained from 
clinical trials testing a novel DNA-based therapy which exploits the use of a lncRNA 
promoter. In this case, H19 gene promoter is incorporated into a DNA-vector 
carrying a diphtheria toxin-A gene and the cancer cells with induced H19 expression 
are selectively killed by the toxin they produce from the DNA-vector (Gofrit et al, 
2014; Lavie et al, 2017). H19 is a widely studied tumorigenic lncRNA (reviewed in 
Yoshimura et al, 2018) and this approach may be applicable for various cancers with 
active H19 expression. There are several lncRNAs with a tumorigenic function and 
targeting them by antisense oligonucleotides (Katsushima et al, 2016; Amodio et al, 
2018) or synthetic ribozymes (Kim et al, 2017; Kharma et al, 2016) delivered in 
extracellular vesicles would be a favorable approach as a cancer treatment (reviewed 
in Jiang et al, 2017). Another strategy is to inhibit lncRNA interaction with a protein 
or protein complex and this kind of steric hindrance would prevent the undesired 
function of the lncRNA (Finkel et al, 2017; Sarma et al, 2010; Mahmoudi et al, 2009). 
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Currently, there are several potential lncRNA cancer markers and treatment 
approaches under investigation (reviewed in Chandra Gupta & Nandan Tripathi, 
2017) and it seems that it is only a matter of time before lncRNAs can be utilized in 
clinical use. 
6.2 The role of lncRNAs in cSCC progression 
6.2.1 Evaluation of differentially expressed lncRNAs in cSCC 
The functional role of lncRNAs in cSCC development is not well known. Valuable 
clues about functionally relevant lncRNAs can be obtained from transcriptomic 
profiling studies. However, the detailed characterization of lncRNAs in vitro and in 
vivo is needed to evaluate their potential use as cancer biomarkers or therapeutic 
targets. In this work two lncRNAs, PICSAR and PRECSIT, were identified and 
characterized, and they may have functional relevance in cSCC progression. Based 
on the transcriptome profiling PICSAR and PRECSIT were noted among the most 
differentially expressed lncRNAs in cSCC cells compared to NHEKs. Localization of 
PICSAR was noted primarily in the cytoplasm, whereas PRECSIT was mainly 
localized in the nucleus by analyzing cellular fractions of cSCC cells. Their expression 
was further evaluated in situ in a panel of tissue samples from NS, AK, SK, cSCCIS 
and invasive cSCC. Expression of both lncRNAs was significantly induced in cSCC 
when compared to NS. Expression of PICSAR was absent in NS, whereas PRECSIT 
was expressed at very low level, suggesting that both may be prominent markers in 
early cSCC development. 
There are several gene expression profiling studies of cSCC available, however 
the lncRNA expression data of cSCC is very limited. This is partly due to the fact that 
most of the newly annotated lncRNA transcripts are not included in these gene 
expression microarrays. To our knowledge, we are the first ones to demonstrate 
lncRNA expression in situ in cSCC tissues, indicating the lack of detailed 
characterization of these molecules in cSCC. Very likely there are several functional 
lncRNAs yet to be discovered. While most of the transcriptional profiling studies of 
cSCC are focused on protein coding mRNAs, currently only one lncRNA expression 
profiling study of cSCC has been published (Sand et al, 2016). Supporting our work, 
PICSAR was reported also as one of the top induced lncRNAs in cSCC in that study 
(Sand et al, 2016).  
Interestingly, comparison of other known lncRNAs with our RNA-seq analysis 
of cSCC cells and NHEKs (GSE66412) revealed that lncRNAs TINCR and DANCR 
were also regulated, even though they did not reach the statistical significance. 
TINCR is induced during epidermal differentiation and its downregulation may be 
associated with cSCC (Kretz et al, 2013; Ponzio et al, 2017). In consistent with this, 
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TINCR was downregulated in cSCC cells compared to NHEKs based on our RNA-
seq analysis (GSE66412). Conversely, DANCR expression was induced in four out 
of eight cSCC cell lines compared to NHEKs, showing a similar trend with the 
lncRNA expression profiling study by Sand and colleagues (Sand et al, 2016). 
DANCR is not implicated with cSCC in the literature, however its role in suppressing 
epidermal differentiation may suggest a tumorigenic link for DANCR in cSCC 
progression. Additionally, LINC00319 which was shown to be induced in cSCC (Li 
et al, 2018) was also upregulated in five out of eight cSCC cell lines when compared 
to NHEKs in our RNA-seq data (GSE66412). Similarly, LINC00520 which was 
recently shown to be downregulated in cSCC (Mei & Zhong, 2019) showed 
analogous downregulation in our RNA-seq analysis (GSE66412). Two known tumor 
suppressor lncRNAs, MEG3 and GAS5, were downregulated in cSCC cells compared 
to NHEKs based on our RNA-seq analysis (GSE66412). Interestingly, MEG3 
expression was noted in only two out of six cSCC cell lines, indicating epigenetic 
MEG3 gene silencing in these cells, which is frequently reported in many cancers 
(Gao et al, 2017; Zhang et al, 2010; Anwar et al, 2012). 
6.2.2 LncRNA PICSAR promotes cSCC growth by regulating 
ERK1/2 activity 
The molecular pathogenesis of cSCC is widely studied and aberrant activation of the 
MAPK pathway is one of the central drivers of the disease (Lambert et al, 2014; Su et 
al, 2012; Einspahr et al, 2012). The p38 MAPK is an important factor in regulating 
cellular stress response, such as the solar UV-radiation, however activation of p38 is 
strongly implicated in skin carcinogenesis (Schindler et al, 2009; Liu et al, 2013; 
Junttila et al, 2009), in particular the p38α and p38δ MAPK isoforms that are 
predominantly expressed by cSCC cells (Junttila et al, 2009). To study the role of p38 
in PICSAR expression, p38 activity was blocked by using specific p38 inhibitors, 
siRNAs and adenoviral delivery of dominant negative mutant of MKK3b, an 
upstream activator of p38α and p38δ. Inhibition of the p38α and p38δ resulted in 
PICSAR upregulation. However, inhibition of ERK1/2 MAPK did not affect PICSAR 
expression, indicating PICSAR as a target for p38 signaling pathway in cSCC cells.  
The functional studies revealed that PICSAR knockdown suppressed the 
proliferation and migration of cSCC cells and growth of cSCC tumors in vivo. 
Knockdown of PICSAR significantly decreased the levels of activated ERK1/2, a well-
studied transcription factor controlling cell proliferation. ERK1/2 is a downstream 
effector on the MAPK pathway and it is shown to be activated by UVA radiation (He 
et al, 2004; Bachelor & Bowden, 2004). Moreover, mutational activation of EGFR 
leads to sustained activation of the RAS-RAF-MEK-ERK MAPK pathway, 
supporting the role of ERK1/2 activation in cutaneous carcinogenesis (reviewed in 
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Wee & Wang, 2017; Uribe & Gonzalez, 2011). These results suggest that the 
functional effect of PICSAR involves regulation of the ERK1/2 pathway. RNA-seq 
for PICSAR knockdown cSCC cells was performed and among the most upregulated 
genes after PICSAR knockdown was DUSP1 (dual specificity phosphatase 1) 
encoding a phosphatase with a wide substrate specificity for various MAP kinases 
(reviewed in Patterson et al, 2009). In addition to DUSP1, DUSP6 was also 
upregulated in PICSAR knockdown cSCC cells. DUSP6 is localized both in the 
cytoplasm and nucleus, and it is activated on binding to ERK2 and it specifically 
dephosphorylates and inactivates ERK2, but not JNK or p38 MAP kinases (Groom 
et al, 1996; Muda et al, 1998). In this context, a possible regulatory link between 
PICSAR, DUSP6 and ERK1/2 was further investigated. In the presence of DUSP6 
inhibitor PICSAR knockdown had no effect on ERK1/2 activation, suggesting that 
PICSAR is regulating ERK1/2 activation via DUSP6. PICSAR may inhibit DUSP6 
expression in cSCC cells by regulating its mRNA stability, directly or indirectly, 
indicated by the cytoplasmic localization of PICSAR. Together, these findings 
identify PICSAR as a tumorigenic lncRNA in cSCC by activating ERK1/2 and 
inducing cSCC cell growth via DUSP6 suppression (Figure 8).  
 
Figure 8. Proposed molecular function for PICSAR in cSCC. 
Very little is currently known about PICSAR in cancer. PICSAR has been shown to 
be upregulated in MDA-MB-231 cells when compared to MCF-7 cells (Shi et al, 
2017). These are both commonly used breast cancer cell lines but they differ greatly 
in their molecular background. The MCF-7 cells present a luminal ephitelial 
phenotype with oestrogen receptor expression whereas the MDA-MB-231 cells are 
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highly aggressive, lacking oestrogen and progesterone receptor expression, and they 
present a mesenchymal phenotype (reviewed in Holliday & Speirs, 2011). PICSAR 
expression was detected in both cell lines but it was substantially induced in MDA-
MB-231 compared to MCF-7 cells, indicating an association with breast cancer 
progression (Shi et al, 2017). Conversely, PICSAR has been shown to be 
downregulated in stage I lung adenocarcinoma, suggesting its tumorigenic function 
may be specific for only certain cancer types (Tian et al, 2017). PICSAR upregulation 
in cSCC cells and breast cancer cell lines (Shi et al, 2017) may tell something about 
its functional role in the epithelial cells. Lung adenocarcinomas originate from the 
lung epithelium as well, however their molecular background is different from lung 
squamous cell carcinomas and they arise from different anatomical locations 
(reviewed in Kadara et al, 2016). PICSAR has been reported to be expressed in the 
brain tissue, specifically in the white matter (Mills et al, 2013). In addition, PICSAR 
downregulation is associated with male infertility and defective spermatogenesis (Lü 
et al, 2015). This supports a hypothesis that PICSAR may have an important 
functional role in maintaining normal homeostasis in certain cell types, however if 
induced in the inappropriate tissue it may promote cancer progression. 
6.2.3 The functional role of PICSAR in cSCC cell migration 
and adhesion 
To further characterize the functional mechanism of PICSAR its role in cell 
migration was investigated. Decreased migration of individual cSCC cells was noted 
on collagen I and fibronectin after PICSAR knockdown together with a significant 
increase in cell adhesion on these matrices. Also, the morphology of PICSAR 
knockdown cells was less spherical and the cells had more lamellipodia compared to 
control cells. The RNA-seq data of PICSAR knockdown cells was explored to find 
differentially expressed genes specially mediating cell adhesion. Several of these 
genes were regulated, particularly ITGA2, ITGA5 and ITGB1 genes encoding α2, α5 
and β1 integrin subunits. They form the functional heterodimeric α2β1 and α5β1 
membrane proteins, which function as cell surface receptors for type I collagen and 
fibronectin. Their mRNA expression was increased after PICSAR knockdown and 
the flow cytometry analysis confirmed increased expression of the α2, α5 and β1 
integrins also on the cell membrane. These observations indicate that PICSAR is 
regulating cell adhesion and migration by mediating integrin expression in cSCC 
cells. Indeed, cell migration is dependent on the optimal balance in integrin 
expression and the changes in the affinity of integrin-ligand binding (Palecek et al, 
1997). With increased integrin expression cell adhesion is also increased due to 
higher number of integrin bonds to the extracellular matrix, resulting in decreased 
migration rate (Palecek et al, 1997). 
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To support our findings, stably PICSAR overexpressing cSCC cells were 
generated to study how this affects cell adhesion and migration. The mRNA levels of 
α2, α5 and β1 integrins were significantly decreased in PICSAR overexpressing cells. 
Also, their expression on the cell surface was decreased based on the flow cytometry 
analysis. PICSAR overexpression resulted in impaired cell spreading and the number 
of spread cells was significantly decreased in PICSAR overexpressing cells. In 
addition, adhesion of PICSAR overexpressing cSCC cells was decreased together 
with an increase in cell migration. These observations are in accordance with our 
findings with PICSAR knockdown cSCC cells, supporting the role for PICSAR in 
cSCC cell adhesion and migration. 
The exact molecular mechanism how PICSAR controls integrin expression 
remains unanswered. The level of Src expression was noted to correlate with PICSAR 
expression. Src expression was decreased after PICSAR knockdown and increased in 
PICSAR overexpressing cells, indicating a regulatory link between these molecules. 
Src has an important role in regulating integrin-mediated cell spreading and 
adhesion by a direct interaction with integrins, but it also regulates cell motility by 
controlling focal adhesion turnover (Fincham & Frame, 1998; reviewed in Playford 
& Schaller, 2004). The morphological effects that were observed in cSCC cells after 
PICSAR knockdown or overexpression are supported by the previous reports where 
the introduction of a constitutively active variant of cellular Src into normal cells 
leads to a disruption of cell-matrix adhesions and a rounded phenotype (Wang & 
Goldberg, 1976; Fincham et al, 1995). In contrast, the catalytically inactive c-Src-
mutant increases actin stability and formation of enlarged focal adhesions, which 
eventually leads to decreased cell motility (Fincham & Frame, 1998). These findings 
suggest that PICSAR mediates adhesion and migration of cSCC cells by regulating 
integrin expression on the cell surface. PICSAR regulates also the expression of Src, 
which may contribute to regulating cell adhesion by mediating integrin affinity (Li 
et al, 2002) and actin stability (Fincham & Frame, 1998) (Figure 8). 
6.2.4 LncRNA PRECSIT promotes cSCC progression by 
regulating STAT3 and MMP expression  
LINC00346, which was later named PRECSIT, was found among the most 
upregulated lncRNAs in cSCC cells compared to NHEKs, suggesting a tumorigenic 
role in cSCC progression. PRECSIT (LINC00346) upregulation has been reported in 
breast, bladder, pancreatic, non-small cell lung and hepatocellular cancers (Liu et al, 
2016; Ye et al, 2017; Zhang et al, 2018; Wang et al, 2017; Zhang et al, 2015), however 
its subcellular localization, expression in situ or the detailed functional mechanism 
in these cancers have not been investigated.  
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The low level of PRECSIT expression in NHEKs and normal skin suggested a 
correlation between the p53 mutational status and PRECSIT, as the p53 is frequently 
mutated early in cSCC carcinogenesis (Pickering et al, 2014; South et al, 2014). The 
mutational status of the p53 protein is routinely assessed in many cancer types by 
visualizing the nuclear accumulation of the mutant p53 by immunohistochemical 
analysis (reviewed in Soussi & Béroud, 2001). Total absence of the protein may also 
imply nonsense mutation in TP53 resulting in a lack of functional p53 (Sakatani et 
al, 1998). The p53 staining intensities in our panel of tissue sections of normal skin, 
seborrheic keratosis, actinic keratosis, cSCC in situ and invasive cSCC were in 
accordance with the previous reports, where the strong or moderate nuclear 
accumulation of p53 is noted early in cSCC carcinogenesis (Einspahr et al, 1999; 
Bukhari et al, 2009; Kim et al, 2006; Onodera et al, 1996). Interestingly, TP53 
mutations are not seen in seborrheic keratoses, which are benign skin tumors with a 
clear UV mutation signature (Hafner et al, 2010; Duperret et al, 2014). In accordance 
with this, a very low level of nuclear accumulation of mutated p53 was noted in 
seborrheic keratosis tissue sections, indicating a functional p53 in vivo in these 
lesions. 
PRECSIT expression was examined together with p53 expression levels in vivo 
in parallel tissue sections. Low or moderate PRECSIT expression was noted in most 
of the NS and SK tissues with low p53 staining intensity, suggesting that PRECSIT is 
suppressed by functional p53 expressed in vivo in these lesions. A high level of 
variation in PRECSIT expression level and p53 staining intensities was noted in AK, 
cSCCIS and invasive cSCC tissues and it seems that the percentage of PRECSIT 
positive cells is not directly correlated with p53 mutational status. However, when 
the p53 staining intensities was compared in tissue samples detected with PRECSIT 
accumulation (≥ 5 PRECSIT particles per cell) the majority of these cSCC lesions 
were negative for p53, suggesting that a high PRECSIT copy number per cell could 
be related to the absence of p53 expression in vivo. It remains to be elucidated 
whether a very low basal level of PRECSIT is actually important for normal 
regulation of keratinocytes, whereas a significant induction of PRECSIT due to 
mutationally inactivated p53 could be associated with cSCC progression. 
Significantly higher expression of PRECSIT was noted in HaCaT cells with 
homozygously mutated p53 compared with NHEKs with functionally active p53. 
Moreover, adenoviral delivery of the wild-type p53 into HaCaT or cSCC cells with 
mutated p53 resulted in downregulation of PRECSIT expression in cSCC cells. These 
results show for the first time that PRECSIT is a p53 regulated lncRNA in cSCC cells. 
The regulatory network between lncRNAs and p53 has been actively studied and 
several p53-regulated lncRNAs have been identified so far (Sánchez et al, 2014; 
Léveillé et al, 2015). Vice versa, lncRNAs such as MALAT1, RoR and MEG3 have 
been shown to regulate p53 (Tripathi et al, 2013; Zhang et al, 2013; Zhou et al, 2007). 
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However, their cellular mechanisms of action differ from one another. A recent study 
shows that MALAT1 can regulate acetylation of p53 by binding to nuclear protein 
deleted in breast cancer 1 (DBC1) thus inhibiting the interaction of DBC1 with 
sirtuin 1 (SIRT1), a histone deacetylase known to deactivate p53 (Chen et al, 2017). 
MEG3 instead promotes p53 stability indirectly by downregulating the mouse 
double minute 2 homolog (MDM2) (Zhou et al, 2007). MEG3 has been also shown 
to inhibit cell proliferation in the absence of p53, suggesting a tumor suppressive 
function for MEG3 (Zhou et al, 2007). The functional mechanism how p53 regulates 
PRECSIT expression remains unanswered. It may be that PRECSIT is 
transcriptionally inhibited by a specific transcription factor which is induced by p53 
activation, or PRECSIT may be also epigenetically regulated. 
To date, only few studies have reported about functionally relevant lncRNAs in 
cSCC, in addition to our studies. A recent study reveals MALAT1 as a pro-
carcinogenic lncRNA in cSCC (Zhang et al, 2019). The authors demonstrate a 
functional mechanism for MALAT1 in interacting with c-MYC and transcriptionally 
activating kinectin 1 (KTN1) which results in positive regulation of EGFR protein 
expression (Zhang et al, 2019). In addition to MALAT1, LINC00319 was shown to 
be upregulated in cSCC and its expression was correlated with tumor size and 
lymphovascular invasion (Li et al, 2018). Supporting this finding, in our RNA-seq 
analysis of NHEKs and cSCC cells (GSE66412) LINC00319 expression is very low in 
NHEKs but induced in five out of eight cSCC cell lines. LINC00319 was shown to 
promote cell proliferation, migration and invasion (Li et al, 2018). Interestingly, 
induction of MMP-2 and MMP-9 was shown to correlate with LINC00319 
upregulation and cell invasion. LINC00319 regulatory mechanism was 
demonstrated by regulation of cyclin‐dependent kinase 3 expression via miRNA 
binding (Li et al, 2018), however the exact way how this affects MMP expression is 
not clear.  
Marked downregulation of MMP-1, MMP-3, MMP-10 and MMP-13 expression 
was noted both at mRNA and protein levels after PRECSIT knockdown in cSCC cells 
and this was demonstrated to be a result of decreased levels of activated STAT3 after 
PRECSIT knockdown. STAT3 functions as a transcription factor for several MMPs, 
including MMP-1 and MMP-3 (Itoh et al, 2006; Tsareva et al, 2007), and it has shown 
to mediate invasion signaling via MMP induction. MMP-3 and MMP-10 are 
stromelysins, capable of degrading several ECM-components and they can promote 
cSCC progression by activating latent MMPs, including MMP-1 and MMP-13 
(reviewed in Ala-aho & Kähäri, 2005). Accordingly, elevated expression of MMP-3 
and MMP-10 has been reported in cSCC (Boyd et al, 2009; Kerkelä et al, 2001). 
Additionally, MMP-13 is specifically expressed in head and neck SCCs (HNSCC) 
(Stokes et al, 2010) and in malignant squamous epithelium of the skin (Airola et al, 
1997) and it is potently inhibited by p53 (Ala-aho et al, 2002). Therefore, these results 
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identify a mechanism how p53 inhibits invasion of cSCC cells by suppressing the 
expression of PRECSIT (Figure 9).  
 
Figure 9. Proposed molecular function for PRECSIT in cSCC. 
Decreased invasion of cSCC cells through collagen type I matrix was noted after 
PRECSIT knockdown. Additionally, inhibition of STAT3 by a small-molecule 
inhibitor resulted in decreased levels of MMPs and cell invasion, supporting the role 
for STAT3 in controlling invasion of cSCC cells. Overall, these observations indicate 
that the decreased invasion of cSCC cells noted after PRECSIT knockdown is due to 
decreased levels of MMPs, which in turn are dependent on transcriptional activation 
by STAT3. Decreased level of activated STAT3 was noted after PRECSIT 
knockdown, indicating that PRECSIT specifically regulates invasion of cSCC cells 
via STAT3 signaling (Figure 9).  
The in vivo xenograft assay revealed that PRECSIT knockdown results in 
decreased tumor growth. When looking at PRECSIT expression in the control 
xenograft tumors the highest level of PRECSIT expression was noted at the tumor 
edges with a similar localization with active STAT3 when compared with the inner 
tumor mass, indicating that PRECSIT may be associated with tumor invasion and 
proteolytic activity of MMPs at the invading edge of tumors (reviewed in 
Kessenbrock et al, 2010). It may be that the decreased tumor growth after PRECSIT 
knockdown is a result of impaired tumor cell implantation and organization of the 
ECM at the early stage of tumor formation. Together, these findings indicate that 
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PRECSIT promotes progression of cSCC by specifically regulating invasion of cSCC 
cells via STAT3 signaling (Figure 9). 
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7 Summary and Conclusion 
In this study the role of lncRNAs in cSCC progression was studied in culture and in 
vivo. Two lncRNAs, LINC00162 and LINC00346, were selected for investigation as 
they were the top most induced lncRNAs in cSCC cells when compared to NHEKs, 
suggesting them as prominent tumor promoting factors. 
Induced expression of LINC00162 and LINC00346 was noted in cSCC cells in 
culture and in tissues of AK, cSCCIS and invasive cSCC in vivo when compared to 
NHEKs and normal skin. Primarily cytoplasmic localization was noted for 
LINC00162, whereas LINC00346 was mainly localized to the nucleus.  
LINC00162 expression was shown to be inhibited by the p38 signaling pathway. 
Knockdown of LINC00162 expression resulted in decreased ERK1/2 activation, 
inhibition of cell proliferation and migration, and inhibition of growth of cSCC 
xenografts in vivo. RNA-seq of cSCC cells after LINC00162 knockdown revealed 
altered expression of several genes, including DUSP6, an ERK2 specific dual-
specificity phosphatase. In the presence of DUSP6 inhibitor LINC00162 knockdown 
did not lead to decreased ERK1/2 activation, indicating DUSP6 as a regulatory link 
between LINC00162 and ERK1/2. Based on these observations, this lncRNA was 
named PICSAR (p38 inhibited cutaneous squamous cell carcinoma associated 
lincRNA). PICSAR was also shown to mediate cSCC cell adhesion and migration on 
fibronectin and collagen I by regulating the expression of cell surface receptor 
integrins. 
Expression of LINC00346 was shown to be regulated by the p53 pathway. RNA-
seq of cSCC cells after LINC00346 knockdown revealed STAT3 as one of the top 
downregulated genes together with MMP-1, MMP-3, MMP-10 and MMP-13. 
Knockdown of LINC00346 suppressed cSCC cell invasion in culture and growth of 
human cSCC xenografts in vivo. Decreased invasion was demonstrated to be a result 
of decreased level of activated STAT3 and production of MMPs. Based on these 
findings it was named PRECSIT (p53 regulated carcinoma-associated STAT3-
activating long intergenic non-protein coding transcript). 
In conclusion, PICSAR and PRECSIT are lncRNAs with a tumorigenic role in 
cSCC. They may serve as novel biomarkers and putative therapeutic targets for cSCC 
progression. 
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